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Novel prevention and therapeutic treatment for cartilage degradation is urgently called
for, as cartilage degradation is a hallmark for arthritic diseases including osteoarthritis (OA) and
rheumatoid arthritis (RA), and there is a high incidence of arthritis-related disability and high
medical costs. While both underuse (e.g. physically inactive lifestyle) and overuse (e.g. high
impact or intense repetitive joint use as seen in certain sports) are risk factors for cartilage
degradation, recent studies highlight that dynamic moderate loading is associated with reduced
incidence of developing OA. Exercise is prescribed in most cases at moderate levels for both OA
and RA patients, and accumulating studies demonstrate appropriate exercise maintains cartilage
homeostasis and may exert a role in chondroprotection, but the mechanisms underlying how
mechanical signals are translated into chondroprotective actions are largely unknown.
Identifying the molecules that mediate mechanotransduction and its mechano-responsive nature
will not only provide a biomechanical basis for developing more effective mechanical loadingbased exercises for chondroprotection, but also can provide novel targets or molecular switches
to develop chemical-based modalities for disease treatment.

The overall objectives of this dissertation were to determine the mechanical response of
transcriptional regulator CBP/p300 Interacting Transactivator with ED-rich Tail 2 (CITED2) to
various mechanical loading regimes, elucidating CITED2-mediated chondroprotective pathways,
and determining the potential of CITED2 as a target for the prevention and treatment of cartilage
degradation in arthritis. The global hypothesis was that CITED2 mediates a mechanical pathway
of chondroprotection, CITED2 is required for cartilage integrity, and restoration or increasing
levels of CITED2 exerts efficacy in the prevention and treatment of cartilage degradation. This
hypothesis was tested with four specific aims: 1) To determine the gene expression response of
CITED2 to various mechanical loading regimes, and the role of CITED2 in mediating
mechanical regulation of matrix metalloproteinases (MMPs), 2) To determine the CITED2mediated loading-induced pathway and test whether it is required for loading-induced
downregulation of MMPs, 3) To determine whether deficiency of CITED2 is a causal factor for
cartilage degradation in arthritic diseases such as OA, and 4) Test the concept of CITED2 as a
target for chondroprotection.
The key findings of this dissertation include: 1) CITED2 expression is induced by
moderate dynamic loading in chondrocytes in an intensity- and duration-dependent manner, and
the upregulation of CITED2 is sustained for at least 12 hours after loading. The induction of
CITED2 is required for the downregulation of MMPs (i.e. MMP-2, -3, and -13), 2) Dynamic
moderate loading induces CITED2 by activating p38δ, which in turn triggers Sp1 and HIF-1α to
transactivate CITED2. CITED2 competes with MMP transactivator Ets-1 for binding to limiting
amounts of co-factor p300, resulting in repression of MMP expression.

3) Deficiency of

CITED2 is associated with cartilage degradation in human OA and disease progression of posttraumatic OA in mice subject to destabilization of the medial meniscus (DMM). Experimental

knockdown of CITED2 caused cartilage degradation and deletion of CITED2 in adult cartilage
not only resulted in an early OA phenotype, but also accelerated the disease progression of
cartilage degradation in DMM mice, revealing a chondroprotective role of CITED2, which is
required for cartilage integrity maintenance. 4) Restoring levels of CITED2, via gene transfer or
small molecule epigallocatechin gallate (EGCG), exerts efficacy in slowing cartilage degradation
in RA and OA mouse models.

Together, these studies provide feasibility for developing

CITED2-activation-based therapies for the prevention and treatment of cartilage degradation.
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Figure 3.1. Schematic of intermittent hydrostatic pressure loading device. Cell

38

culture plates sealed in sterile bags were loaded in a pressurized chamber
interfaced to an Instron 8511 servo-hydraulic loading frame.
Figure 3.2. Loading intensity-dependent induction of CITED2 and suppression

38

of MMP expression. (A) mRNA and (B) protein expression of CITED2 and
MMP-2, -3, and -13, 1 hour after intermittent hydrostatic pressure (IHP) loading
at 1.0, 2.5, 5.0, and 7.5 MPa, at 1Hz for 1 hour, in C28/I2 chondrocytes.
n=5/group. *=p<0.05 compared to unloaded controls.
Figure 3.3. Time- and magnitude-dependent effects of IHP loading on CITED2

39

and MMP expression. (A) mRNA and (B) protein expression of CITED2 and
MMP-2, -3, and -13 after 1 hour of IHP loading for 0.25, 0.50, 1.0, 3.0, and 6.0
hours of IHP at 2.5MPa and 1Hz, in C28/I2 chondrocytes.

n=5/group.

*=p<0.05 compared to unloaded controls.
Figure 3.4. Post-loading effect of IHP on CITED2 and MMP expression. (A)

39

mRNA and (B) protein expression of CITED2 and MMP-2, -3, and -13 at 0.25,
0.5, 1, 3, 6, 12, and 24 hours after IHP for 3 hours at 2.5MPa and 1Hz.
n=5/group. *=p<0.05 compared to unloaded controls.
Figure 3.5. CITED2 is required for moderate IHP-induced suppression of MMPs
(A) mRNA and (B) protein expression of MMP-2, -3, and -13 in chondrocytes
treated with CITED2 siRNA with or without IHP (2.5MPa, 1Hz, 1hr).
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n=5/group. *=p<0.05 compared to unloaded controls.
Figure 3.6. Overexpression of CITED2 mimics the effect of moderate IHP-

40

induced suppression of MMPs. (A) mRNA and (B) protein expression of MMP2, -3, and -13 in chondrocytes transfected with plasmids carrying 0.1 or 1.0 μg
of human CITED2 cDNA, or vector controls. n=5/group. *=p<0.05 compared
to untransfected controls.
Figure 3.7. Cited2+/- mice exhibited a reduced level of Cited2 and elevated levels of

41

MMPs compared to age and gender-matched wild-type littermates. The Effect of
moderate treadmill running (10m/min, 1hr, 0° incline) on suppressing expression of
MMP-1, -2, -3, and -13 which was observed in wild-type mice, was diminished in
Cited2+/- mice. n=3/group. *=p<0.05.
Figure 4.1. In vivo motion knee joint motion loading device. The schematic diagram

63

of the in vivo device (left). Experimental setup with a rat undergoing the motion and
loading protocol (right).
Figure 4.2. Passive motion loading prevents cartilage degradation. (A) Schematic
representation of the Short Protocol, where the rat hind limb is immobilized for six
hours interrupted by 1-hour of passive motion or release from immobilization under
anesthesia, or the (D) Extended Protocol, where the rat limb is immobilized for 7 days
with or without a 1-hour per day passive motion protocol. (B, E) qPCR showing foldchange in mRNA levels of MMP-1 or (C, F) CITED2, and (G) MMP-1 (enzyme)
activity after immobilization (Im), passive motion loading (Pm), sham treatment (Sh),
or no treatment (Con). (H) Safranin O staining and immunohistochemical localization
ii

64

of MMP-1, type II collagen denaturation (Col2-3/4M antibody), and CITED2 in
articular cartilage from rats undergoing the Extended Protocol. Statistics: One way
ANOVA and Tukey’s post hoc test, *p < 0.05 versus control, n=5 rats per group. Scale
bar = 100 µm.
Figure 4.3. CITED2 is required for load-induced downregulation of MMP-1. (A, B)
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qPCR showing the effect of intermittent hydrostatic pressure loads (IHP, MPa as
shown, 1 Hz, 1 hour) applied to articular cartilage explants (n=5 rats per group) or to
(C, D) chondrocytes on CITED2 and MMP-1 mRNA expression and (E) CITED2 and
MMP-1 protein expression detected by Western blot. (F, H) qPCR and (G) Western
blots showing, respectively, the effect of transfecting chondrocytes with pcDNA3.1CITED2 or small interfering RNAs for CITED2 (si-CITED2) or scrambled RNA (siScramble) on MMP-1 mRNA and protein expression in response to IHP (2.5 MPa,
1Hz, 1 hour) in the absence or presence of IL-1β. *p < 0.05, versus control, in
triplicate.
Figure 4.4. Direct effects of CITED2 and p300 on MMP-1 promoter transactivation.
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Chondrocytes were co-transfected with CITED2, Ets-1 and p300 in various
combinations (shown) with or without siRNA for p300 (si-p300) or IHP (2.5 MPa, 1
Hz, 1 hour). MMP-1 promoter activity was measured by luciferase assay. *p < 0.05,
versus vector transfected cells, in triplicate.
Figure 4.5. CITED2 competes with Ets-1 for p300 binding. (A) Immunoprecipitation
of protein lysates from chondrocytes subjected to IHP, CITED2 overexpression or
CITED2 knockdown with anti-p300 antibody and Western blot (WB) with either anti-

iii

67

CITED2 or anti-Ets-1 antibodies to reveal protein-protein interactions between Ets-1,
CITED2 and p300.

(B) qPCR showing the effects of overexpressing p300 or

dominant-negative p300 (p300-DN) on the relative expression of MMP-1, CITED2 and
p300 in response to IHP (2.5 MPa, 1Hz, 1 hour) or (C) co-transfection with wild type
CITED2 without IHP. Mean half-maximal inhibitor concentrations (IC50, nM) for (D)
CITED2 on Ets-1-p300 or (E) Ets-1 on CITED2-p300.
Figure 4.6.

CITED2 regulates MMP-1 through specific motif.

(A) Effect of

68

transfecting chondrocytes with plasmids encoding either wild-type (WT) CITED2 or
CITED2 deleted, truncated, or point mutants on (B) MMP-1 and CITED2 mRNA
(PCR) and/or protein (Western blot) expression in the presence of IL-1β. Abbrev: CR
– conserved region; ∆srj – CITED2 wild-type with deletion of 39-amino acid serineglycine rich junction; EPEE – mutated LPEL (aa243-246) motif. (C) Effect of cotransfecting wild-type Ets-1 or Ets-1 deleted or truncated mutants with CITED2 on (D)
MMP-1 and CITED2 mRNA (PCR) and/or protein (Western blot) expression in the
presence of IL-1β.
Figure 4.7. MAP Kinase p38δ is the upstream mediator of CITED2 in response to
moderate loading. qPCR showing the effect of IHP (MPa as shown, 1 Hz, 1 hour) on
the expression of (A) CITED2 and (B) MMP-1. (C) Western blot showing p38δ and
p38α activation, measured as phosphorylation of the p38 substrate, ATF2.

(D)

Luciferase activity in chondrocytes transfected with the CITED2 promoter-reporter
construct after application of IHP (2.5 MPa, 1 Hz, 1 hour), or co-transfection with wildtype or dominant negative p38δ or p38α, or (E) with sequential deletion constructs of
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CITED2 co-transfected with p38δ. *p < 0.05 versus control, wild-type, or previous
deletion construct, in triplicate.
Figure 4.8. CITED2 mimics suppression of MMPs 1, 2, 3, and 13 in chondrocytes in

70

the presence of IL-1β by wild-type CITED2 but not functional domain deleted
CITED2. (A)

Transfection of wild-type CITED2 but not EPEE mutant suppressed

MMP gene expression and activity in chondrocytes in the presence of IL-1β. Upper
panel: Wild-type and CITED2 mutant constructs. EPEE is a mutation of the LPEL
motif found within the 224-256 amino acid region.
overexpression of wild-type and mutant CITED2.

(B) Western blot showed

(C) ChIP analysis with Ets-1

binding sites on MMP promoters shows that increased Ets-1 binding after IL-1β
treatment was prevented with CITED2 overexpression. n=3/group. *=p<0.05.
Figure 5.1. Conditional knockout of Cited2 gene in the cartilage of adult mice.

80

Intraperitoneal injections of Tamoxifen (1mg/10g/mouse/day for 5 days) into 6months-old

male

and

female

inducible

Cited2

conditional

KO

mice

(Col2a1CreERTxCited2fl/fl)64,65 completely and specifically knocked out the
Cited2 gene in mouse articular cartilage. ( A) Mouse crossbreeding strategy to
generate Cited2 conditional KO mice. ( B) Validation of exclusive Cited2 knockout at
the DNA, mRNA and protein levels 12 weeks after Tamoxifen administration. WT:
age and gender matched wild type control mice. KO: Col2a1CreERTxCited2fl/fl
mice receiving Tamoxifen dissolved in corn oil; Sham: Col2a1CreERTxCited2fl/fl
that received corn oil without Tamoxifen. NC: negative control without sample.
Figure 5.2. Reduced levels of CITED2 are associated with increased OA severity, and
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increased degradation of cartilage matrix components. (A) Safranin O staining, and
immunohistochemistry for CITED2, cleaved aggrecan (NITEGE) and denatured type II
collagen (Col2 3/4M) in human OA (B) and mouse OA (destabilization of the medial
meniscus, DMM) cartilage, compared to age and gender-matched non-OA controls.
n=5/group.
Figure 5.3. CITED2 knockdown by intra-articular gene transfer of CITED2 shRNA

82

for 2 weeks in wild-type mice (male, C57Bl/6, 10-12 weeks) (A) or conditional
knockout of Cited2 (Cited2 cKO) in the articular cartilage for 8 weeks (male, Cited2flf
x Col2al-CreERT, 10-12 weeks) (B) led to early OA, and increased the amount of
cleaved aggreacan and denatured type II collagen in the articular cartilage compared to
sham (A) or wild-type littermates (B). DMM in Cited2 cKO mice increased severity of
OA and increased cleaved aggrecan and denatured type II collagen compared to wildtype littermates (C). n=5/group.
Figure 5.4. (A) Reductions in CITED2 expression were associated with decreases in

83

chondrocytes expressing MMP-13 and ADAMTS-5 in human and mouse OA cartilage,
compared to non-OA controls. (B) Experimental knockdown of Cited2 in mouse
articular cartilage by intra-articular gene transfer of CITED2 shRNA or (C) conditional
knockout led to increases in MMP-13 and ADAMTS-5 compared to non-knockdown
controls. n=6/group.
Figure 5.5. CITED2 represses ADAMTS-5 expression by negatively regulating
syndecan-4. (A) Level of syndecan-4 was elevated in CITED2 conditional knockout
mice (cKO) which was associated with elevated levels of ADAMTS-5. (B) CITED2
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gene transfer reduced the levels of both syndecan-4 and ADAMTS-5 in DMM
cartilage. Cell counts of syndecan-4, ADAMTS-5, and CITED2 in conditional
knockout mice vs wild-type, and in DMM+vehicle vs. DMM+CITED2. n=5/group.
*=p<0.05.
Figure 6.1. Increased expression of CITED2 by gene transfer exerts chondroprotection

96

in CIA rats. Top: Experimental protocol, transfection efficiency of CITED2 gene
transfer, and expression of CITED2 in CIA rats throughout the experiment. Bottom:
CITED2 gene transfer prevented degradative changes within the articular cartilage in
the CIA model. Gene transfer prevented loss of Safranin O staining, and decreased
expression of MMP-13 and ADAMTS-5. n=8/group.
Figure 6.2.

Intra-articular CITED2 gene transfer reduced OA severity, increased
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CITED2 expression, and prevented damage to aggrecan and type II collagen in the
cartilage of DMM mice after 4 weeks, compared to vehicle-treated controls.
n=6/group.
Figure 6.3. Green tea extract, epigallocatechin-3-gallate (EGCG, 100 µM), induces

98

expression of CITED2 in C28/I2 human chondrocytes. *p < 0.05 versus control, n=3.
Figure 6.4. EGCG administration slows progression in early and mid-stage OA in
DMM mice. Safranin O staining and OARSI score of sham- or DMM-operated mice
treated with vehicle or EGCG at 4 (A, B) weeks following surgery (*p<0.05, ANOVA,
n=6/group). Arrows heads indicate the areas of cartilage fibrillation or erosion, and
arrows indicate loss of Safranin O staining.
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Figure 6.5. EGCG administration reduced the degradation of type II collagen in the
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articular cartilage matrix. Immunohistochemical staining of type II collagen cleavage
epitope (Col2 3/4M) and relative staining intensity of the articular cartilage matrix of
sham- or DMM-operated mice treated with vehicle or EGCG at 4 (A, B) weeks
following surgery (*p<0.05, ANOVA, n=6/group, Scale bar=100µM).
Figure 6.6. EGCG administration reduced the degradation of aggrecan in the articular
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cartilage matrix. Immunohistochemical staining of cleaved aggrecan (NITEGE) and
relative staining intensity in the articular cartilage matrix of sham- or DMM-operated
mice treated with vehicle or EGCG at 4 (A, B) weeks following surgery (*p<0.05,
ANOVA, n=6/group, Scale bar=100µM).
Figure 6.7. EGCG administration reduced MMP-13 levels in the articular cartilage.
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Immunohistochemical staining of MMP-13 and percentage of MMP-13 positive cells in
the articular cartilage of sham- or DMM-operated mice treated with vehicle or EGCG
at 4 (A, B) weeks following surgery (*p<0.05, ANOVA, n=6/group, Scale
bar=100µM).
Figure 6.8. EGCG administration reduced ADAMTS5 levels in the articular cartilage.
Immunohistochemical staining of ADAMTS5 and percentage of ADAMTS5 positive
cells in the articular cartilage of sham- or DMM-operated mice treated with vehicle or
EGCG at 4 (A, B) weeks following surgery (*p<0.05, ANOVA, n=6/group, Scale
bar=100µM).
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Chapter 1. Introduction and Background

1.1 Research Significance
Cartilage degradation is a hallmark of joint diseases such as osteoarthritis (OA) and
rheumatoid arthritis (RA).1 These joint diseases result in joint pain accompanied by varying
degrees of functional limitation and reduced quality of life. They affect more than 27 million
Americans, and are one of the leading causes of pain and disability worldwide.2,3 In response to
articular cartilage damage as seen in OA or RA, cartilage exhibits increased cell activity and new
tissue production in an attempt to repair the damage. However, the intrinsic repair is limited and
deregulated. Cartilage degradation is usually a continuous process, leading to erosion of the
articular surface and eventual joint failure.2,4
There is currently no cure or effective treatment for arthritis. Treatments thus far mainly
focus on the secondary effects of joint diseases such as pain and joint function, but there are no
effective

disease-modifying

therapies

for

cartilage

degradation.5,6

Potentially

useful

pharmacologic therapies (i.e. matrix metalloproteinase inhibitors) have seen limited clinical
benefit, and severe side effects.7 A better understanding of the pathogenesis of cartilage
degradation will be required to achieve significant advances in the development of effective
strategies for the prevention and treatment of joint diseases such as OA and RA.
Moderate exercise is the most common non-pharmacologic therapy prescribed to patients
with arthritis. The Arthritis Foundation promotes an exercise program involving low-impact
physical activity, and participants have reported less pain and fatigue, and increased strength.8
Clinical trials of patients with OA report physical activities including aerobic exercise,
1

stretching/flexibility, endurance training, aquatic exercise, and muscle strengthening lead to
improvements in pain relief, body weight, and metabolic abnormalities.9 In addition to the
symptom-modifying effects of exercise, there is evidence of exercise exerting disease-modifying
effects. For example, increased physical activity in the form of aerobic and weight-bearing
exercises results in increased proteoglycan content, one of the major components of the cartilage
extracellular matrix, in the cartilage of OA patients.10 Strength training for 30 months, compared
to range of motion exercises alone, leads to a decreased mean rate of joint space narrowing.11
While the clinical benefits of dynamic moderate exercise are significant, mechanisms
underlying the effects of physical activity on the joint are not well understood. Experimental
studies in animal models of osteoarthritis and human cartilage tissues ex vivo suggest moderate
exercise also leads to increased anti-catabolic, anti-inflammatory, and anabolic activity.2
Dynamic stimulation of cartilage explants increases synthesis of cartilage matrix components
and physiologic loading of animals with experimental osteoarthritis suppresses expression of
inflammatory mediators (e.g. interleukin-1β and tumor necrosis factor-α) and enzymes which
directly cleave the articular cartilage including matrix metalloproteinases (MMPs) and A
Disintegrin And Metalloproteinase with Thrombospondin Motifs (ADAMTS).2 Focusing on
elucidating the mechanisms underlying the chondroprotective effects of physiological joint
loading may provide novel insights aimed at maintaining cartilage health.
1.2. Joint Physiology in healthy cartilage
Articular joints consist of two bony ends with cartilaginous end plates sheathed by a soft
envelope of synovium. The cartilaginous plates, consisting of chondrocytes and at least seven
species of collagen, but mostly Type II, cushion the bony ends during repeated compression and
2

enable them to slide with minimal friction.12 The metabolic needs of the avascular cartilage are
met by nutrients and waste products diffusing through the synovial fluid and into and out of the
synovium and its blood vessels and lymphatics.13 Fat, collagen, and glycosaminoglycans
constitute the deformable synovial sheath. Synovial lining cells synthesize joint lubricants,
matrix molecules, digestive enzymes, and cytokines.12
Cartilage structure and composition
Articular cartilage lines the ends of bones in synovial joints and provides an almost
frictionless surface for motion.14
type:

Cartilage is anueral and avascular and consists of one cell

the chondrocyte, which is embedded in an extracellular matrix (ECM) of collagen

molecules and proteoglycans (PGs). Chondrocytes account for approximately 5% of the total
volume of the cartilage, while water constitutes 70-80% of the total tissue weight.15 Collagen
molecules, of which type II is the predominant form, constitute about 75% of the dry tissue
weight. They form a matrix with tensile strength, which allows cartilage to resist swelling.15
Aggrecan, which is the most abundant proteoglycan in cartilage, accounts for approximately
25% of the dry tissue weight.16

Aggrecan monomers attach to hyaluronan to form large

aggregating complexes within the cartilage fiber meshwork. These monomers consist of a
protein core to which numerous negatively charged glycoaminoglycans side chains attach.17 Due
to this negative charge the PGs confer onto the extracellular matrix, the cartilage becomes
hydrophilic, resulting in a swelling of the tissue which aids in load support and tissue recovery
from deformations.18
The structural properties of cartilage vary with its depth and the cartilage matrix can be
categorized into a superficial, middle, and deep zone. In the superficial zone, collagen fibers are
3

densely packed and aligned parallel to the articular surface, and chondrocytes appear flattened in
shape. Collagen fibers in the middle zone are randomly oriented and chondrocytes appear larger
and more rounded than in the superficial zone. Collagen fibers in the deep zone are oriented
perpendicular to the bone and chondrocytes are aligned in radial columns.19 Aggrecan content is
lowest in the superficial zone, highest in the middle, and decreases in the deep zone.20 The halflife of aggrecan core protein ranges from 3 to 24 years. The proteoglycans are essential for
protecting the collagen network, which has a half-life of more than 100 years if not subjected to
inappropriate degradation.21 Under homeostatic conditions, chondrocytes do not divide, and are
responsible for maintaining the cartilage extracellular matrix through the synthesis of matrix
components and remodeling of the matrix.22
1.3. Cartilage degradation
Osteoarthritis
Osteoarthritis (OA) is the most common joint disease, affecting the structural and
functional integrity of articular cartilage, as well as the adjacent bone and other joint tissues in an
estimated 15% of the U.S. population.3 Clinical symptoms associated with OA include joint
pain, stiffness, and swelling, which may lead to impaired physical function.23 OA is generally
diagnosed radiographically by bony changes, including joint space narrowing, development of
osteophytes,

subchondral sclerosis, and subchondral cyst formation.24

These clinical and

radiographic features are most commonly diagnosed in the knee, hip, and hand joints.23
Although the most evident morphological sign of OA is the progressive destruction of
articular cartilage, and OA is classified as non-inflammatory arthritis, synovitis may also play a
role in the progression of cartilage degradation. Mononuclear cell infiltration and synovial and
4

subchondral angiogenesis are frequently present in OA joints,25-29 resulting in synovial
hypertrophy and hyperplasia with an increased number of lining cells.26,30 Increased numbers of
immune cells (e.g. activated B cells and T lymphocytes) in synovial tissue are also observed,31
leading to the induction of cytokines interleukin-1β (IL-1β) and tumor necrosis factor-α (TNFα),29 and the production of proteases which target the cartilage extracellular matrix.30 These
cartilage breakdown products can further provoke the release of degradative enzymes from
synovial cells.32 Therefore, in developing therapeutic strategies against cartilage degradation, the
effect of the adjoining joint tissues should be considered.
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a systemic inflammatory disease that produces a progressive
degeneration of the musculoskeletal system. RA is characterized by both joint inflammation and
destruction of bone and articular cartilage.33 One of the most prevalent chronic conditions, RA is
found in approximately 1% of the adult population in the United States.34 Disabilities associated
with RA can lead to a restriction of regular daily activity and diminished quality of life.35 Even
with appropriate drug therapy, up to 7% of patients remain disabled to some extent 5 years after
disease onset and 50% are too disabled to work 10 years after onset.34 Consequently, RA results
in considerable direct and indirect costs.
Etiology and risk factors of OA
The initiating factors of OA are unknown, and the exact temporal sequence of events
involving changes in an early OA articular joint are not well defined. However, risk factors for
developing OA have been defined, and are broadly divisible into 1) biomechanical risk factors
including joint injury, occupational/recreational over usage, reduced muscle strength, joint laxity,
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joint malalignment, 2) constitutional factors such as ageing, gender and obesity, and 3) genetic
factors.

Importantly, several risk factors are reversible (i.e. obesity, muscle weakness) or

avoidable (i.e. recreational joint trauma) which has important implications for prevention.36
Injuries of the knee articular cartilage surfaces are frequently observed in athletes and
recreational participants of high-impact sports, including football, basketball, and soccer.37-39
These cartilage injuries are frequently associated with other acute injuries, such as ligament or
meniscal injuries, traumatic patellar dislocations, and osteochondral injuries.40-42 For example,
articular cartilage defects are reported in up to 50% of athletes undergoing anterior cruciate
ligament reconstruction.40,43 Besides acute injury, articular cartilage defects can develop in the
high-impact athletic population from chronic pathologic joint-loading patterns, such as joint
instability or misalignment.40-42 Repetitive intense joint loading is also observed in individuals
with physically demanding occupations, including construction workers, metal workers, farmers,
and pneumatic drill operators. The consequence of either acute or chronic high-intensity loads is
frequently cartilage degeneration, which may eventually lead to osteoarthritis.44-46
With respect to obesity, the prevalent view has been that the mechanical effect of excess
body weight is the direct cause of OA. However, recent evidence suggests the systemic effects
of metabolic factors associated with obesity are major contributors to OA pathogenesis. Obesity
is associated with an increased amount of adipose tissue, which is recognized as having potent
endocrine activity and can give rise to chronic or low-grade inflammation.47,48

Leptin, a

hormone produced mainly by adipose tissue, has been suggested to be an important factor in the
link between OA and obesity.49 Elevated levels of leptin have been found in the synovial fluid in
the knees of patients with OA, and have also been found to be expressed by OA chondrocytes.49
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Increased amounts of fat—with elevated levels of arachidonic acid, a precursor to
proinflammatory prostaglandin E2—have been identified in the bone marrow of patients with
endstage OA.50
Aging is the one of the most influential risk factors for developing OA. While 7.6% of
the 18-44 age group, and 29.8% of the 45-64 age group report doctor-diagnosed arthritis, 50% of
persons aged 65 or older are diagnosed with arthritis.51 Although aging is generally not viewed
as the cause of OA, aging events within articular chondrocytes may predispose the joint to
damage when exposed to mechanical loads. One of the most prominent age-related changes in
chondrocytes is the exhibition of a senescent phenotype,52,53 which is the result of several factors
including the accumulation of reactive oxygen species and advanced glycation endproducts.54-58
Compared to a normal chondrocyte, senescent chondrocytes exhibit an impaired ability to
respond to many mechanical and inflammatory insults to the cartilage matrix.59-63 Furthermore,
protein secretion is altered in aging chondrocytes, demonstrated by a decrease in anabolic
activity and increased production of pro-inflammatory cytokines and matrix degrading
enzymes.64,65 Together, these events may make the articular cartilage matrix more susceptible to
damage and lead to the onset of osteoarthritis.
Etiology of RA
The cause of RA is unknown and the pathogenic process may be initiated by several
different events.

The initial stages of RA involve the initiation and establishment of

autoimmunity, followed by an inflammatory response, angiogenesis to maintain the chronic
inflammatory state, and tissue degradation of the joint.66 During the inflammatory process, the
usually thin layer of synovial lining cells becomes greatly enlarged from the influx of monocytes
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and lymphocytes from the circulation and from the local proliferation of fibroblasts, giving rise
to a synovial hypertrophy called a pannus.67 This pannus formation contains activated B and T
cells, plasma cells, mast cells, and particularly activated macrophages, which are involved in
feeding back to perpetuate inflammation.

Central to this inflammatory response in the

rheumatoid joint are high levels of inflammatory mediators, cytokines, and growth factors,68
including TNF-α, IL-1β, IL-17, and transforming growth factor (TGF)-β.69
New blood vessels form following the inflammatory response, in a process known as
angiogenesis, to maintain the inflammatory state by transporting nutrients to the developing
pannus and inflammatory cells to sites of synovitis.70,71 Angiogenesis is regulated by many
inducers and inhibitors, including acidic and basic fibroblast growth factors (bFGF), TGF,
angiopoietin, placenta growth factor, and vascular endothelial growth factor (VEGF).72 VEGF, a
dimeric glycoprotein which induces formation of new blood vessels and increases vascular
permeability,72 is highly expressed in the synovial tissues of RA patients, and serum levels of
VEGF correlate with RA disease activity.73 VEGF knockout mice show reduced RA disease
activity and synovial angiogenesis in antigen-induced models of arthritis,74 suggesting that
inhibiting VEGF-mediated angiogenesis is likely to suppress rheumatoid inflammation.
Pathology of OA
Articular cartilage, often considered the central focus of OA, plays an essential role in
joint function and has a limited ability for self-repair. The function of articular cartilage is to
distribute mechanical loads across the entire joint surface and provide a nearly frictionless
surface for joint articulation.75 In OA, the loss of articular cartilage leads to joint dysfunction,
resulting in severe disability and pain. Breakdown of the articular cartilage extracellular matrix
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(ECM) involves destruction of its two primary components – type II collagen and proteoglycans.
Degradation of the collagen fiber network and the loss of proteoglycans is one of the early events
which precede the loss of cartilage tissue.75 Due to its avascular nature, articular cartilage
exhibits a limited ability for repair, and damage to the cartilage matrix may continue to progress
into more advanced lesions, resulting in osteoarthritis.
The most common and generally accepted theory of the pathogenic mechanisms of
primary OA involves the cumulative effects of continuous mechanical wear and tear on cartilage.
In the model of biochemical cartilage degeneration, the initiation and progression of primary OA
is linked to time/age-related modifications of resident cartilage matrix components, as well as
age-dependent changes in the properties of newly synthesized and secreted matrix components,
which together culminate in a structurally and functionally inferior cartilage matrix.46 It has
been hypothesized that the pathophysiological process of OA can be described by several
stages.76 At the beginning, the matrix–network degrades on a molecular level. The water content
increases and the size of matrix molecules, namely aggrecan, decreases. The structure of the
collagen network is damaged, which leads to reduced stiffness of the cartilage. In the second
stage, chondrocytes try to compensate the damage by enhanced proliferation and metabolic
activity. Cell clusters surrounded by newly synthesized matrix molecules develop, which is
referred to as cloning.

This condition can remain for several years. In stage three, the

chondrocytes are not able to keep up their repair activity and a complete loss of the cartilage
tissue is the consequence.77
Pathways of cartilage destruction in OA include cell death, cell activation and abnormal
differentiation of remaining chondrocytes, degradation of the extracellular matrix, and
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production of inflammatory mediators.21 While the extracellular matrix of articular cartilage is
the primary target of osteoarthritic cartilage degradation, chondrocytes have a pivotal role during
osteoarthritis, as they are mainly responsible for the anabolic–catabolic balance required for
matrix maintenance and tissue function.78

Chondrocytes may exhibit abnormalities during

osteoarthritic cartilage degeneration, such as inappropriate activation of anabolic and catabolic
activities, and alterations in cell number through processes like proliferation and (apoptotic) cell
death.79 As the disease progresses, osteoarthritic chondrocytes can no longer maintain cartilage
matrix integrity.
There are many modes of interaction between the cells and the extracellular matrix. The
cellular phenotype of chondrocytes is significantly influenced by the derangement or removal of
the pericellular matrix or ECM to which these cells are adapted.80 The cells are affected by
biomechanical stimuli that are transferred through the matrix as well as by the direct modulating
function of specific matrix components. For example, fragments of fibronectin, one of the
degraded matrix components typically found in OA joints, have been reported to induce severe
matrix-degrading effects.81 Chondrocytes are also directly influenced by proteolytic enzymes
and their inhibitors, which diffuse into the cartilage matrix from the surrounding synovial space.
The ability of chondrocytes to maintain matrix homeostasis is severely impaired in osteoarthritic
cartilage, in which the chondrocytes not only fail to compensate for matrix damage induced
externally by factors such as mechanical stress or enzymatic degradation through synovial
proteases, but also have a direct role in the degradation process. Osteoarthritic chondrocytes
activate or upregulate the expression of many matrix-degrading proteases, such as the matrix
metalloproteinases (MMPs), which are largely responsible for the breakdown of the collagenous
and noncollagenous cartilage matrix components.78 The major collagen backbone (type II
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collagen) is cleaved mainly by collagenase 3 (MMP-13) and further degraded by gelatinases
(MMP-2 and MMP-9) as well as by other enzymes.82 As for the primary enzyme that degrades
primarily aggrecan, the major proteoglycan present in cartilage tissue, studies using mouse
models suggested that ADAMTS-5 (a disintegrin and metalloproteinase with thrombospondin
motifs) might be the most important aggrecanase enzyme involved in cartilage destruction.83,84
In OA, increased proteolytic activity is not sufficiently counterbalanced by an increase in
chondrocyte anabolic activity.

Although there is an overall activation of anabolism in

osteoarthritic chondrocytes, this increase in anabolic activity seems to decline and the anabolic
defense reaction eventually fails.85
Suppressing elevated levels of MMPs and ADAMTS in arthritis should be regarded to
have substantial clinical benefit; however, a safe and effective inhibitor has not yet been
developed. MMP inhibitors used in clinical trials have so far failed to show significant efficacy
in human diseases and in some instances resulted in side effects such as joint swelling and
musculoskeletal pain.86 The side effects of MMP inhibitors were attributed largely to their lack
of selectivity because metalloproteinases share structural similarities.87

Unintended MMP

inhibition has been proven to be problematic, because aside from tissue breakdown, MMPs play
critical roles in development, wound healing, and angiogenesis.88,89

For example, MMP-2

knockout mice exhibited more severe clinical and histological arthritis than wild-type mice in an
antigen-induced arthritis model90 and OA development was accelerated in MMP-3 knockout
mice when compared to wild-type mice in a joint destabilization model.91 An alternative noninvasive approach to suppressing MMP and ADAMTS activity may include moderate
mechanical joint stimulation.

Reports have demonstrated the efficacy of physiologic joint

loading such as passive motion therapy in arthritis.92-94 Furthermore, observations that moderate
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loading can antagonize inflammatory cytokine-induced MMP upregulation indicate that such a
strategy might be therapeutically useful.92,93
Although chondrocytes can occasionally divide, adult articular cartilage is usually
classified as a post-mitotic tissue with very little cellular turnover.95 Adult cartilage has no
external cell supply from the vasculature, nor any sort of germinal cell layer to compensate for
any form of cell death or damage that occurs in cartilage degeneration. Consequently, any type
of cell death results in serious disruption of tissue homeostasis.96 Morphological analysis of
osteoarthritic cartilage has suggested the presence of empty lacunae in the matrix, which has lead
to the long-standing assumption that cell death is a central feature in OA.97,98

However,

apoptosis is presumably a rather rare event in osteoarthritic cartilage, as only a small fraction of
apoptotic cells (<1%) are present in normal-aged or osteoarthritic cartilage at any given time
point.95 By contrast, chondrocyte death in post-traumatic lesions seems to be a prominent
issue.99,100 Although the extent and mechanism of cell death in OA is not fully understood, it is
hypothesized that because the chondrocytes are either dead or have insufficient ability to control
the anabolic–catabolic balance, tissue homeostasis is not well maintained. The majority of
chondrocytes in osteoarthritic cartilage are viable, albeit, to a large extent, severely
degenerated.78
Current treatment strategies for arthritis
There is currently no cure for OA. The most successful intervention for OA continues to
be total joint arthroplasty. More than 300,000 total knee arthroplasties are performed each year
within the United States, and that number is expected to increase significantly in the future.101
While total joint replacements, to a degree restore, joint motion and function, there are a few
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drawbacks. First, articular cartilage is replaced with synthetic materials with a finite lifespan,
necessitating a revision surgery if the patient outlives the functional lifespan of the implants.
Secondly, this surgical procedure may have complications such as infection, deep vein
thrombosis, and pulmonary embolus. Finally, arthroplasty will not return patients to a prearthritic level of function because there are no implants that can replicate the biomechanical
characteristics of the native joint.102

For these reasons, it is important to understand the

molecular events that lead to the development of OA, and identify potential targets to slow or
halt disease progression.
Current non-surgical OA treatment strategies mainly focus on mitigating the symptom of
pain.5

Non-steroidal anti-inflammatory drugs (NSAIDs) are effective medications for the

management of mild/moderate OA, due to their analgesic and anti-inflammatory properties, but
have possible gastrointestinal, renal, and cardiovascular side effects.103 Intra-articular injections
are also used in the clinical management of OA, particularly in joints that are easily accessible
such as the knee, shoulder and ankle joints. These injections are typically corticosteroid based or
hyaluronic acid derivatives and may temporarily relieve pain and improve joint lubrication, but
have not been clearly demonstrated to exert disease-modifying chondroprotective effects.103
In fact, there are no disease modifying OA drugs (DMOADs) approved by the Food and
Drug Administration or the European Medicines Agency.7 Due to the role upregulated
MMPs/ADAMTS play in mediating the destructive process in arthritis, inhibitors for these
proteolytic enzymes have been explored as therapeutic strategies to treat OA. However, clinical
trials so far have been met with limited success and resulted in side effects including
musculoskeletal pain and inflammation.104-106 These adverse effects have been mainly attributed
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to the lack of selectivity of these inhibitors.

Matrix metalloproteinases share structural

similarities and are susceptible to regulation by broad-spectrum inhibitors.87 Poor selectivity is
problematic because in addition to matrix remodeling, MMPs/ADAMTS play important roles in
wound healing, angiogenesis, development, morphogenesis, and bone remodeling.88,89 Recent
attempts at developing anti-catabolic drugs have focused on compounds with more selective
profiles and are in early phase development.7 Clearly, pharmacologic solutions for treating OA
need to define the correct molecular targets and ensure proper modulation of these targets.
1.4. Mechanical loading and joint health
In addition to pharmacologic treatment of OA, non-pharmacologic therapies such as
aerobic exercise and strength training are commonly prescribed, and have been reported to exert
protective effects on the joint. A Cochrane Review of 32 clinical trials comparing land-based
therapeutic exercise (i.e. muscle strengthening, aerobics, manual therapy) to a non-exercise
group found that exercise treatment resulted in moderate improvements in pain and physical
function.107 Although clinical trials evaluating the effect of exercise on joint structure in OA
patients are limited, preliminary results from these studies are promising. A 4 month exercise
program consisting of aerobic and weight-bearing exercises resulted in increased proteoglycan
content in the articular cartilage of OA subjects.10 Strength training, compared to range of
motion exercises for 30 months decreased the mean rate of joint space narrowing, but the
difference was not statistically significant.11 Together, while the evidence report that moderate
levels of physical activity improve symptoms of OA and may also exert chondroprotective
effects, these mechanisms are not well understood.
Non-physiologic joint loading
14

Although joints maintain homeostasis within a physiological range of mechanical
loading, both reduced loading and overloading have catabolic effects, particularly for the
cartilaginous components.

Damage to the knee articular cartilage surfaces are frequently

observed in athletes and recreational participants of high-impact sports, including football,
basketball, and soccer.37-39

Articular cartilage damage can also develop from chronic

pathological joint-loading patterns, such as joint instability or misalignment.40-42 These articular
cartilage injuries, as a consequence of either acute or chronic high-intensity loads, will frequently
result in cartilage degeneration, which may eventually lead to osteoarthritis.44,45
Experimental studies show that mechanical overloading can directly damage the cartilage
extracellular matrix and shift the balance in chondrocytes to favor catabolic activity over
anabolism. While direct measurements of in vivo cartilage-on-cartilage contact stresses due to
overuse in human joints have not been made, experimental evidence suggests a range of nonphysiological loading intensities. There appears to be a critical threshold of 15-20 megapascals
(MPa) for cell death and collagen damage due to a single impact load in bovine cartilage
explants.108 In another study on bovine cartilage explants, chondrocyte apoptosis occurred at
peak stresses as low as 4.5 MPa and increased with peak stress in a dose-dependent manner,
while degradation of the collagen matrix occurred in the 7 to 12 MPa range,109 suggesting
chondrocyte apoptosis may precede cartilage matrix damage. In addition to peak stress, strain
rate appears to be an important parameter implicated in cartilage damage. Bovine cartilage
explants compressed at a strain rate of 0.01 s-1 to a final strain of 50% showed in no measurable
effect on biosynthetic activity or mechanical functionality (compressive and shear stiffness) in
chondrocytes, although peak stresses reached 12 MPa,110 a stress high enough to cause injurious
effects such as cell death.109 However, compression at higher strain rates (0.1 and 1 s-1),
15

resulting in peak stresses of about 18 and 23 MPa, reduced total protein biosynthesis and
compressive and shear stiffness,110 suggesting that an increase in peak stress and strain rate is
associated with increased injury. Consistent with these results, high strain rates were reported to
result in significant matrix fluid pressurization and impact-like surface cracking with cell death
near the superficial zone in bovine osteochondral explants.111 Studies also found that repetitive
impact loading of 5 MPa at 0.3Hz induces collagen network damage and chondrocyte necrosis
and apoptosis,112,113 suggesting that impact damage is cumulative. Taken together, the data
indicate that high levels of peak stress, high strain rates, and long-term injurious mechanical
loading are usually correlated with deleterious effects on cartilage. However, caution must be
used when extrapolating these in vitro results to the in vivo situation. Indenters used in these
experiments are likely to cause large stress amplitudes and gradients at the location of impact,
while in normally congruent articular joints, these stresses may be limited due a more even
distribution of force.113 Therefore, the range of non-physiological load intensities in vivo should
be greater than those reported in these in vitro studies.
Similarly to overuse, reduced loading, occurring as a result of spinal cord injuries,114
secondary to treatments for acute musculoskeletal injury,115 or from joint diseases such as
arthritis,116 also results in articular cartilage degradation.

In vivo studies demonstrate that

prolonged joint immobilization causes degradation of the cartilage matrix, characterized by
fibrillation, ulceration, and erosion.117,118 Spinal cord injury patients report articular cartilage
atrophy at a rate greater than that in age-associated osteoarthritis.119 Even during short-term
reduced loading conditions (e.g. 7 weeks of partial weight bearing), a significant degree of
cartilage thinning is reported in all compartments of the knee, although no cartilage lesions are
observed.120
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Cartilage damage from joint overuse and prolonged disuse is often irreversible due to the
avascular nature of articular cartilage, which prevents a physiological inflammatory response.121123

Therefore, spontaneous repair of cartilage is limited, often resulting in biochemical and

metabolic changes resembling early osteoarthritis, such as an accumulation of degradative
enzymes and cytokines, disruption of collagen ultrastructure, increased hydration, and fissuring
of the articular surface.124
Moderate loading of healthy joints
While reduced loading and overloading both cause cartilage degradation, moderate levels
of activity maintain normal cartilage integrity.

Physiologic mechanical stimulation of the

articular cartilage generates biochemical signals which increase the anabolic activity of the
chondrocytes.125-127 Numerous in vitro studies have found increases in proteoglycan synthesis,
collagen II expression, and cell proliferation after dynamic stimulation of chondrocytes in
cartilage explants, 3D and monolayer cultures.126-129 Cyclic pressure-induced strain increased
expressions of aggrecan and superficial zone protein in monolayer cultures130,131 and hydrostatic
pressure in bovine cartilage explants loading increased both proteoglycan production and
aggrecan mRNA synthesis.132,133
Mechanical loading and arthritis
It has been shown that moderate exercise may protect against cartilage degradation in
animals that spontaneously develop OA. Hamsters which ran 6-11 km/day maintained normal
cartilage integrity while their sedentary counterparts developed fibrillation, pitting, and fissuring
in the articular cartilage during this 3-month study.134
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Normal cage activity rats with a

surgically-induced model of OA showed more macroscopic and histologic cartilage degradation
when compared to exercised OA rats which ran 30 cm/s for 30 minutes for 28 days.135
In humans, moderate recreational physical exercise is associated with a decreased risk of
severe knee OA, suggesting that exercise has a protective effect against developing cartilage
degradation.136 Furthermore, moderate joint loading may improve joint health and function in
OA.10

Accumulating studies have demonstrated the effectiveness of non-drug treatment

modalities, e.g., exercise and physical activity, as an adjunct to drug therapy in patients with OA
and RA.137 Consequently, clinical practice guidelines developed to aid health practitioners in
treating osteoarthritis recommend exercise therapy to reduce pain and improve joint function,
based largely on the results of large randomized controlled trials evaluating exercise.138-142
Clinical studies have shown that in RA, moderate exercise has systemic antiinflammatory effects by reducing disease activity.143 In vitro studies have provided evidence for
a direct mechanosensitive mechanism on joint tissues.

Mechanical strain in synoviocytes

decreases expression of prostaglandin-E2 (PGE2),144 an inflammatory mediator, and strain and
shear both decreased the expressions of MMP-1 and -13 in RA synoviocytes.145,146 Furthermore,
chondrocytes exposed to moderate levels of intermittent hydrostatic pressure inhibited IL-1βinduced matrix degradation.147
1.5. CITED2
CBP/p300 Interacting Transactivator with ED-rich tail 2 (CITED2), a transcriptional coregulator, has been suggested to play a role in cartilage matrix homeostasis by suppressing
proteolytic enzyme expression.148 CITED2 was originally cloned and shown to be inducible by
various stimuli including cytokines, serum growth factors, lipopolysaccharide and hypoxia.149,150
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CITED2 encodes a 28-kDa nuclear protein, and is present in a variety of cell types.150 During
early development, CITED2 is widely expressed in both embryonic and extraembryonic cells,
and is involved in regulation of cell proliferation and embryonic development.151

Loss of

CITED2 was shown to result in senescence of cultured fibroblasts,152 while studies with
CITED2-/- animals revealed roles in many different developmental processes, including the
establishment of left-right body axis, and development of cardiac, neural, liver and lung
tissues.151,153
As a co-transcriptional regulator, CITED2 does not possess intrinsic DNA binding
activity. Instead, it functions as a context dependent transcriptional co-activator or co-repressor
via interactions with other proteins.149,154 It has been shown that CITED2 acts as a co-activator
transcription factors such as Lhx2, TFAP2, PPARα, PPARγ, and Smad 2 through, at least in part,
the recruitment of CBP/p300, to act as a positive regulator of transcription. On the other hand,
CITED2 can also negatively regulate the activation of target genes by competing with
transcription factors for binding to factors such as p300. Such a mechanism was established in
hypoxia response, where CITED2 downregulated HIF-1α-induced transactivation by competing
with HIF-1α for binding to p300 via the CH1 domain.149
That CITED2 is able to exert a wide range of regulatory roles in numerous cellular
processes such as cell proliferation and embryonic development is mainly due to the ubiquity of
p300 as a transcriptional co-regulator.149 By binding to p300 via the CH1 domain, CITED2 may
interact, and likely compete, with a multitude of transcription factors including HIF-1α, Ets-1,
NFκB, RXRα, STAT2, MDM2, and p53.155 Since both CITED2 and these other CH1 domain
binding proteins are differentially expressed in various tissue and cell types, CITED2 can act in a
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tissue and stimulus-dependent manner. Therefore, the regulatory roles played by CITED2 should
be understood through its interaction with these function-associated proteins.
Because CITED2 is ubiquitously expressed and regulated by a wide range of stimuli, its
effects vary considerably depending on the nature of the signal and of the cell type. For example,
in chondrocytes, TGF-β induces CITED2 expression, which is consistent with the known role of
TGF-β in downregulating MMP-1 in those cells.148 However, in MDA-MB-231 breast cancer
cells, TGF-β downregulates CITED2 at the post-translational level.156 Similarly, upregulation of
CITED2 under moderate intensities of mechanical loading in chondrocytes leads to
downregulation of MMP-1 and MMP-13, but CITED2 knockdown in SW480 colon cancer cells
results in a mild downregulation of MMP-1.157,158
While CITED2 interacts with a wide range of transcriptional regulators, its own
expression is responsive to several stimuli. The ability of CITED2 to respond to a multitude of
stimuli may be explained by the presence of regulatory elements such as Sp1, STAT, and NF-κB
binding sites in the CITED2 promoter.159

The Sp1 transcription factor-binding site has

previously been identified to be responsive to shear stress and promote gene expression.160 The
deletion and site-directed mutations of the Ets-1 and Sp1 site upstream of the start codon are
critical for CITED2 expression in fibroblasts. Gel mobility shift and supershift assays performed
with Rat1 nuclear extracts identified nucleoprotein complexes binding to the Ets-1 site and the
Sp1 site. In Drosophila SL2 cells, which lack the Sp and Ets family of transcription factors,
expression of Sp1, Sp3, and Ets-1 or Elf-1 functionally stimulated CITED2 promoter activity in a
synergistic manner.161
Role of CITED2 in Mechanotransduction and MMP Downregulation
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CITED2 was considered a likely mediator of mechanically-induced MMP suppression
since it was known to antagonize transcriptional regulators like Ets-1, which have several
binding sites within MMP promoter regions.162 Therefore, Yokota et al. used an immortalized
human chondrocyte cell line C28/I2163 to investigate whether CITED2 was responsive to
mechanical stimuli, and if so, could mediate shear-mediated downregulation of MMP-1 and
MMP-13.148 CITED2 expression at the mRNA and protein levels was found to be inducible by
moderate flow shear. Expression was maximal at 5 dyn/cm2 and basal levels of expression were
found at 0, 10, and 20 dyn/cm2. In contrast, mRNA and protein expression and enzyme activities
of MMP-1 and MMP-13 were upregulated at 0, 10, and 20 dyn/cm2 but were suppressed at 5
dyn/cm2.148

Consistent with these findings, CITED2 expression was recently found to be

inversely related to the expression of MMPs 2, 3, 9 and 13 in fractured bone in a rat mandibular
osteotomy model.

Furthermore, overexpression of CITED2 in osteoblasts inhibited the

expression and activity of MMP-2, -3, -9, and -13.164

Taken together, these data provide

evidence that CITED2 is a mechanical stimuli responsive gene, and its inverse relationship with
MMPs suggests it may play a regulatory role in load-driven MMP downregulation.
To determine the relationship between load-induced CITED2 expression and MMP
downregulation, loss-of-function and gain-of-function approaches were used.

Transfecting

antisense CITED2 plasmids into chondrocytes abolished the loading-mediated downregulation of
MMP-1, suggesting that CITED2 is required by load-driven MMP downregulation.
Overexpression of CITED2 in chondrocytes reduced the basal level of MMP-1 expression under
regular culture conditions, and protected cells from IL-1β-induced upregulation of MMP-1 and
MMP-13.148
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To

elucidate

the

mechanism

of

MMP

downregulation

by

CITED2,

co-

immunoprecipitation with p300 specific antibody was used to identify potential regulatory
proteins in p300 binding protein complexes. This approach was based on the understanding that
CITED2 is not a DNA binding protein, and its role in MMP regulation has to be based on its
interaction with DNA binding transcription factors of MMPs, either directly or via their coregulators such as CBP/p300. Ets-1 was chosen as a primary target since CITED2 and Ets-1 are
known to interact with p300, and Ets-1 is a DNA binding protein which can transactivate MMPs
with p300 as a co-factor.162 C28/I2 chondrocytes were treated with moderate shear at 5 dyn/cm2
or high intensity shear at 20 dyn/cm2. Nuclear extracts were prepared and incubated with
antibody specific for p300 to immunoprecipitate p300 protein complexes. Western blotting
identified equal amounts of p300 in control and treated extracts. In control cells, no p300-Ets-1
or p300-CITED2 complexes were detectable.

In contrast, p300-CITED2 complexes were

identified in cells exposed to flow shear at 5 dyn/cm2 and p300-ETS-1 complexes were detected
in cells under 20 dyn/cm2.148 This study supports the hypothesis that CITED2 may mediate the
mechanical loading-induced downregulation of MMP by competing with MMP transactivator
Ets-1 for limiting amounts of co-factor p300 protein.
Ets-1 proteins comprise a highly conserved family of transcription factors that share a
unique DNA binding domain, the Ets domain.162 The Ets domain specifically recognizes DNA
sequences that contain a GGAA/T core element.165 Ets-1 is a transcription factor that binds to
MMP-1 and other MMP promoter regions.162 The Ets domain also serves as p300 CH1 binding
domain, recruiting p300 as a co-factor in the transactivation of MMPs. The Ets-1 activation
domain or C-domain, is located between amino acids 130–242 and contains a high content of
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acidic residues. It is essential for Ets-1 to activate transcription and is also necessary for the
interaction of Ets-1 with p300.162
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Chapter 2 – Hypothesis and Specific Aims
Mechanical loading has been recognized as the most important factor for cartilage
homeostasis. It contributes critically to maintaining joint tissue homeostasis, especially cartilage
integrity, and may cause cartilage degradation depending on the intensity, frequency, and
duration of loading and form of mechanical loading (e.g. compression, fluid shear, strain, etc.).
Cartilage homeostasis is maintained by balancing anabolic and catabolic activities. Imbalance
between anabolic activity and catabolic activity, especially overactivated catabolic activities in
cases such as overloading, post-trauma, or aging, induces high levels of pro-inflammatory
cytokines and high levels of proteolytic enzymes such as matrix metalloproteinases (MMPs), a
predominant enzyme family that degrades components of the cartilage extracellular matrix. In
contrast, dynamic moderate loading not only enhances anabolic activities such as production of
collagen and aggrecan, the two major matrix components, but also exerts anti-inflammatory
activities.

It has also been reported that dynamic moderate loading such as intermittent

hydrostatic pressure (IHP) suppresses expression and activity of MMP-1, -3, and -13 in
chondrocytes, both in vitro and in vivo. However, how dynamic moderate loading suppresses
MMP expression is largely unknown. Yokota et al. demonstrated that moderate intensities of
flow shear (5 dyn/cm2) increased CITED2 mRNA and protein levels, and down-regulated MMP1 and MMP-13 in chondrocytes. Antisense CITED2 plasmids prevented the shear-induced
down-regulation of MMP expression, while overexpression of CITED2 repressed MMP-1 and
MMP-13 mRNA and protein levels.
These findings led to the hypothesis that CITED2 mediates a mechanical pathway in
chondroprotection; appropriate levels of CITED2 are critical for cartilage integrity; and
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restoration, or increasing levels of CITED2 exerts efficacy in prevention and treatment for
cartilage degradation in arthritis.
Objectives: The overall objective is to determine and characterize the role of CITED2 as a
mechanical inducible transcriptional regulator, identify the novel CITED2-mediated mechanical
sensitive pathway in the downregulation of MMPs, and test the potential of CITED2 as a target
for the prevention and treatment of cartilage degradation in arthritis. Accordingly, four specific
aims are proposed:
Specifically, in Chapter 3 (Specific Aim 1), we will determine whether CITED2
predominately responds to dynamic moderate loading and represses MMPs that are critical for
cartilage integrity in chondrocytes. The study will focus on the gene expression response of
CITED2 to intermittent hydrostatic pressure (IHP), the most relevant mechanical loading
modality articular cartilage experiences under various loading parameters (e.g. intensity,
duration, post-loading time), and determine the role of CITED2 in mediating the mechanical
regulation of MMPs.
In Chapter 4 (Specific Aim 2), we will identify the CITED2-mediated mechanical
signaling pathway that is required for the moderate loading-induced downregulation of MMPs.
This study will focus on the role of CITED2 with its co-activator p300 and MMP transactivator
Ets-1 in regulating MMP expression, and the pathway / signaling molecules that mediate
loading-induced transactivation of CITED2.
In Chapter 5 (Specific Aim 3), we will determine whether CITED2 is required for
cartilage integrity maintenance by determining whether CITED2 is a causal factor for cartilage
degradation in human specimens and mouse surgical and genetic models.
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In Chapter 6 (Specific Aim 4), we will conduct a proof-of-concept study that CITED2 is
a target for chondroprotection by examining the efficacy of CITED2 in slowing or preventing
cartilage degradation via a) intra-articular gene transfer and b) pharmacologically via small
molecule epigallocatechin gallate (EGCG), a compound extracted from green tea that activates
CITED2, using two animal models of cartilage degradation: destabilization of the medial
meniscus (DMM) and collagen-induced arthritis (CIA).
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Chapter 3 – Biomechanical response of CITED2 and role of CITED2 in loading-induced
downregulation of MMPs
Abstract
Mechanical loading is a critical regulator of cartilage homeostasis. While both reduced
loading and overloading lead to cartilage degradation, loading at moderate intensities is required
for the maintenance of the cartilage matrix. The molecular mechanisms which mediate these
loading responses are not well understood.

CITED2 has been previously identified as

transcriptional regulator which is induced by moderate intensities of flow shear, and mediates the
loading-induced downregulation of MMP-1 and MMP-13.

In this study, we examined the

mechanobiologic response of CITED2 to mechanical loading in vitro and in vivo. In vitro, we
determined the effects on chondrocytes of intermittent hydrostatic pressure (IHP), which is
considered the predominant mechanical force chondrocytes experience in vivo.

CITED2

expression was induced by moderate intensities of IHP, at a range of 1.0 to 5.0 MPa, and peaked
at 2.5MPa, when assessed at the mRNA and protein levels in chondrocytes after 1hr of loading at
1Hz for 1hr. CITED2 expression was induced with 15 minutes of IHP, peaked after 3 hours of
loading, and started declining after 6 hours of loading.

The loading-induced response for

CITED2 was transient; CITED2 levels peaked at 3 hours after loading, was elevated until at least
12 hours, and returned to basal levels 24 hours after loading. IHP loading at the range of 1.0 to
7.5 MPa for 1 hr caused the decrease in multiple MMPs, such as MMP-2, -3, and -13, and was
inversely correlated with the CITED2 response at both the mRNA and protein levels under all
the tested loading regimes. The data suggest a role of CITED2 in mediated the loading-induced
downregulation of MMPs, which was further supported by the following evidence: 1)
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overexpression of CITED2 in chondrocytes mimicked moderate IHP-induced suppression of
MMPs in the presence or absence of IL-1β; 2) Moderate treadmill running (10m/min, 1hr, 0º
incline) suppressed MMP-1, -2, -3, and -13 expression in wild-type mice, but this
downregulation was not observed in CITED2+/- mice. The response level of CITED2 may vary
depending on the type of load, which may be critical in developing a CITED2 activation-based
chondroprotection therapies based on mechanical loading.
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Introduction
Mechanical loading is considered to be a critical regulator of skeletal homeostasis.2,166,167
Mechanical loading induces the complex interaction of musculoskeletal tissues including bone,
articular cartilage, and ligaments/tendons.

These mechanical stimuli can be categorized as

beneficial for tissue development and maintenance, or detrimental, which can result in tissue
breakdown and cause joint diseases such as osteoarthritis (OA).
Articular cartilage functions as a nearly frictionless bearing surface while uniformly
transferring loads on underlying bone preventing high stress concentrations. Cartilage consists of
one cell type, the chondrocyte, embedded in an extracellular matrix of mainly type II collagen
and proteoglycans. Cartilage responds to mechanical loading in an intensity-dependent manner.
Acute or chronic high-intensity loads, as seen in athletes participating in high-impact
sports such as soccer, football, and basketball, often predispose the joint to OA.40-42 Joint
injuries, such as anterior cruciate ligament (ACL) tears, similarly increase contact forces in the
knee, and result in degradative changes such as chondral softening and fracture.168,169 Reduced
joint loading also creates catabolic responses within articular cartilage.114,115 Animal models of
reduced loading report that a decrease in mechanical stimuli leads to atrophy of the tissue,170-173
and ultimately erosion of the articular cartilage.117,118 In humans, reduced loading in the form of
partial weight bearing for 7 weeks results in significant cartilage thinning in the knee articular
cartilage120 and spinal cord injury patients exhibit a rate of cartilage atrophy greater than that
reported in age-associated osteoarthritis.119
While reduced loading and overloading both cause cartilage degradation, moderate levels
of activity maintain cartilage homeostasis. Moderate loading of the articular cartilage generates
mechanical signals that increase the synthetic activities of the chondrocyte while suppressing its
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catabolic actions.125-127

In humans, exercise at moderate intensities is associated with a

decreased risk of severe knee OA, suggesting that physical activity has a protective effect against
developing cartilage degradation.136 However, the mechanisms underlying the beneficial effects
of mechanical loading on cartilage integrity are not well understood.
Cartilage degradation, or breakdown of the cartilage extracellular matrix (ECM), involves
a variety of degradative enzymes, many of which are matrix metalloproteinases (MMPs).86,174
The human genome has 24 MMP genes, including two duplicated MMP-23 genes. The MMP
family consists of the collagenases, (MMP-1, -8, and -13) which degrade collagens types I, II,
and III, the gelatinases (MMP-2 and -9), which target denatured collagen, the stromelysins
(MMP-3, -7, -10, and -11), which degrade several ECM proteins and are involved in proenzyme
post-translational activation.
Our previous work has implicated CBP/p300-interacting transactivator with ED-rich tail
2 (CITED2), as a mechanosensitive regulator of MMP-1 and -13.148 CITED2, a transcriptional
regulator, is required for the suppression of MMP-1 and MMP-13 in response to moderate shear.
In this study, we hypothesize that CITED2 mediates a chondroprotective signaling pathway in
which moderate mechanical loading downregulates production of several MMPs in response to
intermittent hydrostatic pressure, a loading stimulus used to mimic the chondrocyte mechanical
environment.175

We will determine the loading duration and intensity-dependent nature of

CITED2 and MMPs expression and the role of CITED2 in the mechanoregulation of MMPs
through loss- and gain-of-function strategies
.
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Materials And Methods
Intermittent hydrostatic pressure (IHP) loading
C28/I2 cells, a human chondrocytic cell line,163 were cultured as high-density monolayers
in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum,
100 μg/ml ascorbic acid, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C.158 Cells
were starved in serum-free DMEM 18 hours prior to intermittent hydrostatic pressure (IHP)
loading in a custom-made device.158 Culture plates were placed in 37ºC water bath in a stainless
steel loading vessel within sterile, heat-sealed bags containing culture medium.

The loading

vessel was maintained within a temperature controlled chamber set at 37ºC. Pressure was
generated within the pressure vessel interfaced with an Instron 8511 servo-hydraulic loading
frame (Fig 3.1). Air was evacuated from the system so the application of pressure was purely
hydrostatic. Control cultures were maintained under identical conditions in heat-sealed bags in a
37ºC water bath not subject to hydrostatic pressure. After loading, cells were lysed for total
RNA or protein isolation, for quantitative PCR or Western blot, respectively.

Transfection of siRNA and plasmids
To knockdown CITED2, C28/I2 cells were transfected with CITED2 siRNA (Santa Cruz,
sc-35959) or a scrambled control (Santa Cruz, sc-37007) 24 hours prior to IHP. To overexpress
CITED2, C28/I2 cells were transfected with pcDNA3.1 plasmids carrying human CITED2
cDNA as described.158

RNA isolation and quantitative PCR
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C28/I2 cells were extracted using the RNeasy mini kit (Qiagen, Valencia, CA) with
DNase treatment according to manufacturer’s instructions.

RNA was quantified with a

Nanodrop spectrophotometer (Thermo Fisher Scientific, Wilmington, DE), then reverse
transcribed (RT) using oligo(dT) primers. Two nanograms of total RNA were analyzed by realtime quantitative PCR with SYBR Green (BioRad) to assess relative gene expression using the 2ΔΔCt

method.176 Target gene expression was quantitated relative to housekeeping gene GAPDH.

Gene (Accession number)

Primer Sequence

CITED2 (NM_001168388.2)

F: 5’-GCGAAGCTGGGGAATAACAA-3’
R: 5’-ATGGTCTGCCATTTCCAGTCT-3’
F: 5’-TCTGGAAGGGCAAGGACTCT-3’
R: 5’-TCCGCTTTTCAACTTGCCTTT-3’
F: 5’-GAGTGCATGAACCAACCAGC-3’
R: 5’-GGGCAGCCATAGAAGGTGTT-3’
F: 5’-TGTTCGTTTTCTCCTGCCTGT-3’
R: 5’-CAGCAGCCCATTTGAATGCC-3’
F: 5’-GCACTTCCCACAGTGCCTAT-3’
R: 5’-AGTTCTTCCCTTGATGGCCG-3’
F: 5’-AATGGGCAGCCGTTAGGAAA-3’
R: 5’-GCGCCCAATACGACCAAATC-3’

MMP-1 (NM_001145938.1)
MMP-2 (NM_001127891.1)
MMP-3 (NM_002422.3)
MMP-13 (NM_002427.3)
GAPDH (NM_001256799.2)

Western Blot
Western blot was performed by using antibodies specific for MMP-1 (Abcam, ab52631),
MMP-2 (Abcam, ab86607), MMP-3 (Abcam, ab18898), MMP-13 (Abcam, ab39012), CITED2
(Santa Cruz, sc-21795) and Actin (ab3280). Approximately 10 µg of the extracted proteins were
separated by electrophoresis (SDS-PAGE) in a 10% polyacrylamide gel, and the separated
proteins were transferred to Immun-Blot PVDF membranes (Bio-Rad, Hercules, CA).
Membranes were incubated with primary antibodies followed by incubation with secondary
antibodies conjugated to horseradish peroxidase (ECL Western blotting analysis system, GE Life
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Sciences, Piscataway, NJ). A mouse antibody specific for β-actin (Sigma-Aldrich, St. Louis,
MO) was used as loading control.

Treadmill running
Cited2+/- carry one allele of Cited2, with the other allele excised and replaced with a neo
cassette.177 These mice were received as a gift from Dr. Yu-Chung Yang. Cited2+/- mice and
wild-type littermates (male, 6 months old) were subjected to 1 hour of treadmill running (1 hour,
10m/min, 0° incline) or regular cage activity. Three hours after this loading regimen, the
articular cartilage from the knee was harvested and flash frozen for RNA isolation. Gene
expression for Cited2, MMPs-1, -2, -3, and -13 were assessed by real-time PCR with GAPDH
used as a housekeeping control.

Statistical Analysis
Results are expressed as mean ± SD. Statistical analysis was carried out using a one-way
ANOVA and Tukey’s test for post hoc analysis with significance set at P < 0.05.

Results
Response of CITED2 and MMPs to IHP loading
IHP induced biphasic changes in the expression of CITED2 and MMP-2, -3 and -13 in
C28/I2 chondrocytes (Fig 3.2A). CITED2 expression by qPCR increased up to 7-fold at 2.5
MPa, returning to basal levels at 7.5 MPa. In contrast, expression of MMP-2, -3, and -13
exhibited biphasic decreases in expression over the same range of IHP. MMP-2 and -13 were
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suppressed most strongly at 2.5 MPa IHP and returned to basal levels at 7.5 MPa, while MMP-3
was less sensitive. Maximal inhibition of MMP-3 was seen at 5.0 MPa, and expression remained
significantly below control levels at the highest pressure tested (7.5 MPa). Corresponding
elevations in CITED2 and reductions in MMPs were also seen at the protein level by Western
blotting (Fig. 3.2B). Expression of all MMPs and CITED2 were inversely correlated, with
correlation coefficients of -0.73, -0.53, and -0.85 for MMP-2, -3 and -13, respectively.
CITED2 mRNA upregulation in response to continued exposure to 2.5 MPa IHP was
rapid; 60% of maximal stimulation was observed after 15 minutes. A plateau of expression
(values not significantly different from the 3 hour maximum value) was achieved by 1 hour and
was sustained through 6 hours, although there appeared to be a trend of declining expression at
the latest time point (Fig 3.3A, 3.3B). Downregulation of MMP-2, -3, and -13 occurred over the
same time interval, although significant reductions were in expression were not seen until 30
minutes of IHP exposure, i.e. following the upregulation of CITED2 (Fig 3.3A, 3.3B). A single
3 hour exposure to IHP induced changes in CITED2 and MMP expression that persisted for up to
12 hr or more, as assessed by real-time PCR and Western blot, respectively (Figs 3.4A and
3.4B).

CITED2 mediated loading-induced suppression of MMPs
The inverse time and dose relationships between CITED2 and MMP expression in
response to IHP suggested that the suppression of MMP expression by moderate loading may
result through the actions of CITED2. To test this possibility, we first suppressed CITED2
expression in C28/I2 chondrocytes with siRNA and found that MMP expression in the absence
of IHP was increased. Moreover, moderate IHP loading (2.5 MPa, 1 hour) failed to suppress
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MMP expression in chondrocytes treated with si-CITED2 (Fig 3.5A). Suppression of MMPs in
the absence of mechanical load was also dependent on the extent of CITED2 overexpression (Fig
3.6A, B).
Loading-induced MMP suppression reduced in Cited2+/- mice
To determine whether the mechanical effect of moderate loading (treadmill running)
would similarly affect expression of MMPs in vivo, and to test whether CITED2 mediates these
loading-induced effects, wild-type and Cited2+/- mice were subjected to moderate treadmill
running for 1 hour or allowed regular cage activity. Without loading, Cited2+/- mice exhibited
50% less Cited2 expression and elevated MMP expression (Fig 3.7).

One hour after this

treadmill running, Cited2 gene expression was elevated and MMP expression was reduced in
wild-type mice, but to a lesser extent in Cited2+/- mice (Fig 3.7).

Discussion
Presently, both resistance and gentle exercises are prescribed for rehabilitation of injured
or arthritic knees. However, the optimal duration and physical loading necessary for achieving
the beneficial effects of exercise are unclear. Defining a physical activity as “moderate or
physiological” is a challenge because loading regimes involve many parameters such as
intensity, frequency and duration, and a “moderate” physical activity for a particular individual
might vary depending on an individual’s age, genetics, gender, and physical activity history.
Therefore, identifying biomarkers associated with moderate loading may provide useful
indicators for choosing the right type exercise/physical activity with a precise loading regime and
therefore increase efficacy of mechanical-based therapies for cartilage protection and treatment.
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We examined the response of CITED2, a transcriptional regulator induced by mechanical shear
which exerts an anti-catabolic role by repressing MMP-1 and -13 expression and activity.148 In
this study, we showed CITED2 was upregulated in response to moderate intensities of IHP,
which was directly related to the downregulation of MMP-2, -3, and -13. This suggests there is a
moderate range of loading which is chondroprotective. As CITED2 only responded to moderate
mechanical loading, it is possible CITED2 expression may be utilized as a biomarker to define
which physical activities may be considered “physiologic.” We also examined the effect of
loading duration, and post-loading time in response to moderate IHP. The induction of CITED2
and suppression of MMP expression plateaued after 1 hour of loading. Furthermore, the upregulation of CITED2 was sustained until at least 12 hours after loading. Together, this suggests,
with regards to chondroprotection, that 1 hour of moderate physical activity once or twice a day
may be sufficient to maintain an anti-catabolic environment within the articular cartilage.
While chondrocytes in vivo experience many types of mechanical forces, such as shear,
strain, and compression, we focused on intermittent hydrostatic pressure loading because it is the
predominant force chondrocytes experience in vivo.178 The fact that CITED2 is responsive to
multiple forms of mechanical loading supports the concept that CITED2 is a mechanically
responsive regulator.
In addition to the role CITED2 played in suppressing MMP-1 and -13 expressions, this
study revealed CITED2 is also a transcriptional regulator for MMP-2, and -3. MMP expression
was reduced but not completely suppressed in response to moderate mechanical loading. This
form of MMP modulation may represent a more physiologic method of regulating MMP
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expression in arthritis, in contrast to complete MMP suppression induced by MMP inhibitors
tested in clinical trials.
The overexpression of CITED2 mimicked the anti-catabolic effects of moderate
mechanical loading on MMP suppression, suggesting CITED2 may be a molecular target for
chondroprotection to suppress excess catabolic activity in arthritis. The activation of CITED2,
by mechanical means may be a therapeutic strategy to slow or arrest cartilage degradation.
However, the mechanisms through which mechanical loads transactivate CITED2 are not
understood and require further elucidation.
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Figures

Fig 3.1. Schematic of intermittent hydrostatic pressure loading device. Cell culture plates sealed
in sterile bags were loaded in a pressurized chamber interfaced to an Instron 8511 servohydraulic loading frame.

Figure 3.2.

Loading intensity-dependent induction of CITED2 and suppression of MMP

expression. (A) mRNA and (B) protein expression of CITED2 and MMP-2, -3, and -13, 1 hour
38

after intermittent hydrostatic pressure (IHP) loading at 1.0, 2.5, 5.0, and 7.5 MPa, at 1Hz for 1
hour, in C28/I2 chondrocytes. n=5/group. *=p<0.05 compared to unloaded controls.

Figure 3.3. Time-dependent effects of IHP loading on CITED2 and MMP expression. (A)
mRNA and (B) protein expression of CITED2 and MMP-2, -3, and -13 after 1 hour of IHP
loading for 0.25, 0.50, 1.0, 3.0, and 6.0 hours of IHP at 2.5MPa and 1Hz, in C28/I2
chondrocytes. n=5/group. *=p<0.05 compared to unloaded controls.
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Figure 3.4. Post-loading effect of IHP on CITED2 and MMP expression. (A) mRNA and (B)
protein expression of CITED2 and MMP-2, -3, and -13 at 0.25, 0.5, 1, 3, 6, 12, and 24 hours
after IHP for 3 hours at 2.5MPa and 1Hz. n=5/group. *=p<0.05 compared to unloaded controls.

Figure 3.5. CITED2 is required for moderate IHP-induced suppression of MMPs (A) mRNA
and (B) protein expression of MMP-2, -3, and -13 in chondrocytes treated with CITED2 siRNA
with or without IHP (2.5MPa, 1Hz, 1hr). n=5/group. *=p<0.05 compared to unloaded controls.

Figure 3.6. Overexpression of CITED2 mimics the effect of moderate IHP-induced suppression
of MMPs. (A) mRNA and (B) protein expression of MMP-2, -3, and -13 in chondrocytes
transfected with plasmids carrying 0.1 or 1.0 μg of human CITED2 cDNA, or vector controls.
n=5/group. *=p<0.05 compared to untransfected controls.
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Figure 3.7. Cited2+/- mice exhibited a reduced level of Cited2 and elevated levels of MMPs
compared to age and gender-matched wild-type littermates. Effect of moderate treadmill running
(10m/min, 1hr, 0° incline) on suppressing expression of MMP-1, -2, -3, and -13, which was
observed in wild-type mice, was diminished in Cited2+/- mice.

41

n=3/group. *=p<0.05.

Chapter 4 - Physiologic Loading Of Joints Prevents
Cartilage Degradation Through CITED2
Abstract
Both overuse and disuse of joints upregulate matrix metalloproteinases (MMPs) in
articular cartilage and cause tissue degradation; however, moderate (physiologic) loading
maintains cartilage integrity. Here we test whether CITED2, a mechanosensitive transcriptional
co-regulator, mediates this chondroprotective effect of moderate mechanical loading. In vivo,
hindlimb immobilization of Sprague-Dawley rats upregulates MMP-1 and causes rapid,
histologically detectable articular cartilage degradation. One hour of daily passive joint motion
prevents these changes and upregulates articular cartilage CITED2. In vitro, moderate (2.5 MPa,
1 Hz) intermittent hydrostatic pressure (IHP) treatment suppresses basal MMP-1 expression and
upregulates CITED2 in human chondrocytes whereas high IHP (10 MPa) downregulates
CITED2 and increases MMP-1. Competitive binding and transcription assays demonstrate that
CITED2 suppresses MMP-1 expression by competing with MMP transactivator, Ets-1 for its coactivator p300. Furthermore, CITED2 upregulation in vitro requires the p38δ isoform, which is
specifically phosphorylated by moderate IHP. Together, these studies identify a novel regulatory
pathway involving CITED2 and p38δ, which may be critical for the maintenance of articular
cartilage integrity under normal physical activity levels.
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Introduction
Mechanical loading is one of the most important environmental factors responsible for
joint homeostasis and there is tremendous concern about how joint motion and load bearing may
impact joint health. Articular cartilage maintains its integrity throughout life under moderate
loading conditions experienced during routine daily activity. In contrast, when cartilage is
subjected either to excessive or insufficient mechanical loading, degeneration occurs. Exposure
of joints to acute and chronic (repetitive) high-intensity loading eventually leads to osteoarthritis
(OA).46,179 On the other hand, the absence of normal mechanical stimulation, as occurs in
paralysis following spinal cord injury, can also cause articular cartilage breakdown through the
induction of a similar catabolic response.171,180 To date, we have begun to define many of the
cellular and molecular processes responsible for these catabolic changes.21 However, the
mechanism through which moderate loads prevent cartilage degradation and maintain functional
capacity remains unknown.
Articular cartilage destruction results from the breakdown of extracellular matrix (ECM)
constituents, primarily type II collagen and aggrecan, whose proteolysis are mediated by matrix
metalloproteinases (MMPs) and a disintegrin-metallo proteinases with thrombo spondin motifs
(ADAMTS), respectively. MMPs comprise a large family of structurally related endopeptidases
and are considered to be the principal mediators of both normal ECM remodeling and pathologic
degradation.181 Of the 26 MMPs identified, MMP 1, 8, and 13 represent the secreted neutral
proteinases capable of cleaving type II collagen.181 MMPs 1 and 13 are highly expressed in the
cartilage and synovium of OA and rheumatoid arthritis patients,182-185 though MMP-8 is not
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appreciably elevated in OA.186 Other MMPs including MMPs 2, 3, and 9 have also been reported
to play a role in the degradation of cartilage ECM.21,187
MMP expression and function are controlled, both positively and negatively, at multiple
levels including transcription and enzyme activity (e.g. via inactivation by specific inhibitors like
tissue inhibitors of metalloproteinases, or TIMPs).86 Upregulation of MMPs in response to
mechanical stimuli has been documented in a wide range of tissues and cells,188 via multiple
signal transduction pathways often involving members of MAP kinase families, e.g. p38 and
p42/44,189 but much less is known about the downregulation of MMP expression by mechanical
loading. In a previous study, we showed that moderate levels of flow shear downregulated
expression of MMP-1 and MMP-13 in human C28/I2 chondrocytes, and that this downregulation
coincided with upregulation of the transcriptional regulator CITED2 (CBP/p300-interacting
transactivator with ED-rich tail 2),148 suggesting that CITED2 may contribute to MMP regulation
in chondrocytes. In the present study we sought to define the role of CITED2 in the regulation
of MMPs by focusing on MMP-1, a prototypical catabolic enzyme that cleaves type II collagen
and is highly expressed in arthritic articular cartilage.183,190

We then determined whether

CITED2 regulates other MMPs such as MMPs 2, 3, 13, through a similar mechanism as with
MMP-1 using a strategy involving mutagenesis of the CITED2 functional motif and a ChIP
assay.

Materials And Methods
Animal Experiments
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Male Sprague-Dawley rats (5-6 months old, 580 ± 35 g) were housed with access to food
and water ad libitum. All procedures were approved by the IACUC of Mount Sinai School of
Medicine. The right hind limbs were immobilized as previously described.191 Briefly, rats were
anesthetized with isoflurane and were fitted with a cast made of steel mesh and cotton materials
which fixed the knee in full flexion (115°). Animals were either left immobilized for the
duration of the experiment, released from casting for 1h under anesthesia (sham) or subjected to
motion loading at a frequency of 2 cycles/minute with a range of motion between 65° and 115°
using a custom-designed loading device.192 The in vivo loading device consisted of an animal
bed and an anesthesia machine integrated into a custom-built knee joint motion/load apparatus, a
linear actuator with micro-stepping driver and digital encoder, a magnetic goniometer for realtime joint angle readout, a load cell for compressive load monitoring, a USB analog/digital I/O
interface module, and LabView control panel (Fig 4.1). The anesthetized animal was placed
prone over an acrylic bed, and the right hind limb of the animal was placed in the knee joint
apparatus. The knee joint apparatus transformed the linear motion provided by the actuator into
angular displacement at the knee joint. The loading device had adjustable control of motion
frequency and range of angular displacement via a linear actuator with 50 mm travel stroke
(bipolar NEMA 13 Hybrid, Haydon Motion, Waterbury, CT) coupled to an incremental rotary
encoder (E5S, US Digital Corp, Vancouver, WA).

After motion loading or release from

immobilization under anesthesia (sham group), the rats were sacrificed or re-cast until the next
motion loading session. The short and extended protocols are described in the ‘Results’ section.
In each protocol, a control group was allowed free cage activity throughout the experiment.
Following sacrifice, cartilage from immobilized knee joints (distal femur, proximal tibia) was
rapidly removed and prepared for MMP activity assays, histology or RNA isolation.
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MMP activity assay
Articular cartilage was dissected, flash-frozen in liquid nitrogen and stored at -80°C.
MMP-1 activity was assayed by using the Senosolyte Plus 520 MMP-1 assay kit (Anaspec,
Fremont, CA).

Frozen tissue samples were pulverized (Dismembrator, B Braun Biotech,

Germany) in MMP activity assay buffer (Anaspec) containing 0.1% (vol/vol) Triton-X 100, and
then centrifuged for 15 minutes at 10,000 g at 4°C. The supernatant was added to a 96-well plate
containing immobilized MMP-1 antibody in the presence of 4-aminophenylmercuric acetate
(APMA) for 3 hours, and its proteolytic activity was measured by the 5-FAM/QXL 520 FRET
peptide (Anaspec). The fluorescence of 5-FAM (fluorophore) was quenched by QXL 520 in the
intact FRET peptide. Fluorescence signal was monitored at Ex/Em=490 nm/520 nm upon
MMP-1 induced cleavage of the QXL FRET substrate. Fluorescent intensity was measured
using the SpectraMax M5 spectrofluorometer (Molecular Devices, Sunnyvale, CA).
Immunohistochemistry and Safranin O staining
Total knee joints were fixed in formalin, decalcified, paraffin-embedded and sectioned.
For immunostaining, endogenous peroxidase activity was blocked with 3% (vol/vol) H2O2 for 5
minutes. Tissues were incubated overnight at 4°C with either anti-CITED2 (1:300, Santa Cruz,
Santa Cruz, CA), anti-MMP-1 (1:100, Abcam, Cambridge, MA), or Col2-3/4M (1:200, Ibex
Pharmaceuticals, Canada), followed by a 30 minute incubation with anti-mouse or anti-rabbit
secondary antibody (Dako, Carpinteria, CA) and visualization with DAB chromagen for 3
minutes. Negative control sections were prepared using irrelevant isotype-matched antibodies in
place of the primary antibody. Safranin O-fast green staining was carried out to demonstrate
glycosaminoglycans in the articular cartilage.
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Cartilage explants, cell culture, and intermittent hydrostatic pressure loading
Articular cartilage from the rat distal femur and proximal tibia were carefully separated
from the underlying bone under a dissecting microscope. The cartilage explants and C28/I2 cells
(cultured as high-density monolayers) were each cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% fetal bovine serum, 100 μg/ml ascorbic acid, 100
U/ml penicillin, and 100 μg/ml streptomycin at 37°C.193 Both the rat articular cartilage explants
and C28/I2 cells were starved in serum-free DMEM 18 hours prior to intermittent hydrostatic
pressure (IHP) loading in a custom-made device.194 After loading, cartilage explants pulverized
in liquid nitrogen and C28/I2 cells were lysed for total RNA or protein isolation, for quantitative
PCR or Western blot, respectively.
Transfection of siRNA and plasmids
C28/I2 cells were incubated with siRNA for CITED2 (Santa Cruz) or transfected with
pcDNA3.1 plasmids constructed to encode cDNA sequences for wild-type (WT) human
CITED2, Ets-1, or mutant forms of CITED2 and Ets-1 with selected sequences deleted using
restriction enzyme digestion and PCR cloning strategies as described.148 In other studies, WT or
mutated human CITED2 cDNA were co-transfected with either WT p300 or a dominant negative
(DN) p300 form in which the CH1 domain was deleted to prevent CITED2-binding (Upstate
Biotechnology, Lake Placid, NY).
RNA isolation and quantitative PCR
Total RNA from flash frozen articular cartilage or C28/I2 cells was extracted using the
RNeasy mini kit (Qiagen, Valencia, CA) with DNase treatment according to manufacturer’s
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instructions.

RNA was quantified with a Nanodrop spectrophotometer (Thermo Fisher

Scientific, Wilmington, DE), then reverse transcribed (RT) using oligo(dT) primers.

Two

nanograms of total RNA were analyzed by quantitative PCR with SYBR Green to assess relative
gene expression, as well as GAPDH and β-actin as housekeepers. PCR primers pairs used were:
rat-MMP-1A,

forward

5’-

ACAGTTTCCCCGTGTTTCAG-3’,

CCCACACCTAGGTTTCCTCA-3’;

human-MMP1,

forward

GGTGACACCAGTGACTGCAC-3’,

reverse

rat/human-CITED2,

TGCCGCCCAATGTCATAG-3’,

forward

5’-

CTGCTGTTTGCACACGAAG-3’;

rat/human-β-actin,

forward

reverse

reverse

forward

5’-

5’5’-

5’-ATGTAGGCCATGAGGTCCAC-3’;

5’-TTGCTGACAGGATGCAGAAG-3’,

ACATCTGCTGGAAGGTGGAC-3’.

5’-

5’-TCCACAAATGGTGGGTACAA-3’;

rat/human-GAPDH,

GAGGACCAGGTTGTCTCCTG-3’,

reverse

reverse

5’-

Expression values of GAPDH and ß-actin for each

treatment condition were averaged and used as a denominator to determine the relative
expression of target genes using the 2-ΔΔCt method.
Western Blot/Immunoprecipitation Assay
Western blot was performed by using antibodies specific for MMP-1 (EMD Chemicals,
Gibbstown, NJ), CITED2 (Santa Cruz). Ets-1 (Santa Cruz), and p300 (Upstate Biotechnology).
Approximately 10 µg of the extracted proteins were separated by electrophoresis (SDS-PAGE)
in a 10% polyacrylamide gel, and the separated proteins were transferred to Immun-Blot PVDF
membranes (Bio-Rad, Hercules, CA).

Membranes were incubated with primary antibodies

followed by incubation with secondary antibodies conjugated to horseradish peroxidase (ECL
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Western blotting analysis system, GE Life Sciences, Piscataway, NJ).

A mouse antibody

specific for β-actin (Sigma-Aldrich, St. Louis, MO) was used as loading control.
For immunoprecipitation, 100 µg of nuclear extracts were mixed with 8 µg of p300specific antibody (Upstate Biotechnology) and incubated with gentle rocking at 4°C overnight.
The immunocomplexes were captured by mixing with protein G-agarose beads for 2 h at 4°C.
The collected agarose beads were washed four times with an ice-cold cell lysis buffer, and the
precipitated proteins were eluted by boiling the beads for 5 min in the SDS sample buffer.
Fractions of the supernatant were analyzed by SDS-PAGE and immunoblotting using antibodies
against p300, CITED2, and Ets-1.
Promoter Analysis and Luciferase Assay
A 510 bp region from the MMP-1 promoter (-468 to +42 relative to the transcription start
site, GenBank M16567) was cloned by amplifying human genomic DNA by PCR and subcloned into the pGL3-Basic Vector (Promega, Madison, WI) immediately upstream of the
luciferase reporter gene. Wild-type and serial deletions of the 5′ end of the CITED2 promoter
region were generated in separate reactions and subcloned into pGL3-basic vector. For the
MMP-1 promoter assay, chondrocytes were transfected or co-transfected with MMP-1 promoter
reporter construct, pcDNACITED2, pCMVp300 (Upstate Biotechnology), pKD-p300-v1 (p300
siRNA), p300 siRNA scramble, and empty vector controls, and/or subjected to IHP loading (2.5
MPa, 1 Hz, 1 hr). For the CITED2 transactivation assay, the cells were transfected or cotransfected with a CITED2 promoter reporter construct, pCMVp38δ WT, pCMVp38δ DN,
pCMVp38α WT, pCMVp38α DN (Cell Biolabs Inc., San Diego, CA), p38δsiRNA (Ambion,
Austin, TX), and/or subjected to IHP loading (2.5 MPa, 1 Hz, 1 hr). For the CITED2 promoter
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serial deletion analysis, wild type and deleted CITED2 promoter reporters were co-transfected
with pCMVp38δ WT into chondrocytes. DNA constructs were transfected into cells using
Lipofectamine Plus Reagent (Life Technologies, Carlsbad, CA). For luciferase assay, cells were
harvested in Passive Lysis Buffer (Promega).

Luciferase activity in the cell lysates was

determined using the Dual-Luciferase Reporter Assay System (Promega). All firefly luciferase
values were normalized for transfection efficiency using the pRL-TK, Renilla-luciferase value.
Peptide Competition Assay
Ets-1 displacement from GST-p300 CH1 (aa302-423) domain by the synthetic CITED2
transactivation domain (TAD) peptide (aa224-255), and CITED2 TAD displacement from the
GST-p300 CH1 domain by Ets-1 TAD peptide (aa153-210) were measured by an ELISA-based
peptide competition assay, as previously described.195 Briefly, increasing amounts of CITED2 or
Ets-1 TAD peptide were added to immobilized biotinylated Ets-1 peptide or biotinylated
CITED2 TAD peptide, respectively. A constant amount of GST-p300 CH1 was then added.
Bound GST-p300 CH1 was quantified by time-resolved fluorescence using europium-labeled
anti-GST antibody (Perkin Elmer, Waltham, MA). Mean half-maximal inhibitor concentration
(IC50) values were calculated for twenty-five separate experiments after fitting data using a nonlinear regression (GraphPad Prism, La Jolla, CA).
Kinase Assay
The phosphorylation of p38 isoforms were conducted using a nonisotopic p38 MAPK
assay kit (Cell Signaling, Danvers, MA) as previously described.196 Briefly, total cell lysates
were prepared from chondrocytes and equal amounts of total protein (100 μg) were precipitated
using p38α or p38δ MAPK antibody, respectively. The activities of precipitated kinases were
50

then allowed to phosphorylate the p38 substrate, ATF2, in the presence of ATP.
Phosphorylation of ATF2 was analyzed by immunoblotting with an antibody specific for
Phospho-ATF2. The expression of p38α or p38δ was confirmed by immunoblotting with the
isoform-specific antibody.
Chromatin immunoprecipitation (ChIP)
C28/I2 human chondrocytes were treated with IL-1β (10ng/ml) to induce MMP
expression, with or without CITED2 transfection. ChIP was performed using a commercial kit
following manufacturer’s instructions (USB). Cell lystes were immunopreciptated with anti-Ets1 (Santa Cruz), and PCR performed using primers specific for Ets-1 binding sites (GGAA/T) in
MMP promoter regions.
Statistical Analysis
Results are expressed as mean ± SD. Statistical analysis was carried out using a one-way
ANOVA and Tukey’s test for post hoc analysis with significance set at P < 0.05.

Results
CITED2 Induction in Articular Cartilage in vivo is Associated With MMP-1 Downregulation
and Anti-catabolic Effects of Joint Motion
To test whether CITED2 mediates the protective effects of physiologic joint motion on
cartilage, we first determined the relationship between of CITED2 and MMP-1 expression under
different mechanical loading regimens. Two protocols were used. In the first “short” protocol,
four groups of rats were treated as follows: (1) no immobilization and no passive motion (Con);
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(2) continuous immobilization for 6 hours (Im); (3) immobilization for 6 hours interrupted by 1hour passive motion (Pm); and (4) immobilization for 6 hours interrupted by a 1-hour release
from the cast under anesthesia, with no passive motion (Sh) (Fig. 4.2A).
Quantitative PCR (qPCR) analysis of articular cartilage samples dissected immediately
after the immobilization period revealed that MMP-1 was upregulated in the immobilizationonly group (Fig. 4.2B). The upregulation of MMP-1 was accompanied by a decline in CITED2
mRNA (Fig. 4.2C). In contrast, passive motion loading applied for 1 hour in the midst of the 6hour immobilization period completely reversed these changes (Figs. 4.2B and 4.2C).
Importantly, simply removing the immobilization stimulus for 1 hour without accompanying
passive motion (sham group), did not reverse the immobilization-induced upregulation of MMP1.
We next extended the immobilization protocol to 7 days and inserted a 1-hour passive
motion loading period each day (“extended” protocol) (Fig. 4.2D). qPCR analysis (Figs 4.2E
and 4.2F) revealed that immobilization stimulated MMP-1 while attenuating CITED2
expression, but both of these changes were prevented upon passive motion loading. We also
measured the activity of MMP-1 and found that it mirrored MMP-1 mRNA levels under all
conditions examined (Fig. 4.2G).
Histological examination of distal femoral articular cartilage revealed evidence of tissue
degradation in immobilized rats, and also indicated that these changes were largely prevented by
passive motion loading (Fig. 4.2H). In particular, immobilization led to decreased Safranin O
staining (indicating reduced proteoglycan content) in the superficial zone of articular cartilage;
this decrease was accompanied by increases in the number of MMP-1-positive cells, stronger
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staining for denatured type II collagen in the superficial and middle zones of the articular
cartilage, and reduction in the number of cells with positive staining for CITED2. By contrast,
passive motion loading of immobilized limbs prevented loss of proteoglycans, limited the
increases in immunohistochemically detectable MMP-1 and denatured type II collagen, and also
increased the number of cells staining positive for CITED2 (Fig. 4.2H, middle and bottom
panels). Taken together, these results indicate that in vivo moderate loading suppresses the
catabolic response to immobilization by inducing CITED2 and downregulating MMP-1.
CITED2 is Required for Moderate Loading-induced Downregulation of MMP-1
In order to assess the regulatory role of CITED2 in MMP-1 expression in vitro and ex
vivo, intermittent hydrostatic pressure (IHP), which is thought to best mimic the loading
environment experienced by articular cartilage in vivo 178, was utilized to mechanically stimulate
freshly recovered rat cartilage explants or cultured chondrocytes. As shown in Figures 4.3A and
4.3B, the application of 2.5 and 5.0 MPa, pressures consistent with those experienced by joints
during walking,185 caused a profound increase in CITED2 and a decrease in MMP-1 mRNA
expression in rat articular cartilage explants. Parallel in vitro studies with chondrocytes showed
qualitatively similar results to those with cartilage explants, namely elevation in CITED2 mRNA
and reduction in MMP-1 mRNA seen best at 2.5 MPa (Figs. 4.3C and 4.3D), as well as
corresponding changes in protein expression on Western blotting (Fig. 4.3E).
To determine whether CITED2 was indeed required for MMP-1 downregulation in
response to mechanical stimuli, we used CITED2 loss and gain of function strategies. A modest,
but significant, increase in MMP-1 mRNA was noted when CITED2 was suppressed by siRNA
knockdown in the basal state (Fig. 4.3F). As expected, loading lowered MMP-1 mRNA, but
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importantly, failed to do so in si-CITED2 transfected cells (Fig. 4.3F). Western blotting showed
an effective reduction of CITED2 protein in the si-CITED2 transfectants, and also demonstrated
their resistance to load-induced MMP-1 downregulation (Fig. 4.3G). Consistently, moderate
loading, as well as CITED2 overexpression, also dramatically inhibited the expression of MMP1 induced by IL-1β, a key mediator of cartilage degradation in both OA and rheumatoid arthritis
197

(Fig. 4.3H). This load-induced suppression of MMP-1 was again abolished in si-CITED2

transfected cells (Fig. 4.3H). These experiments provide clear evidence that, at least in vitro, the
upregulation of CITED2 is required for the load-induced attenuation of MMP-1.
To further demonstrate the critical involvement of CITED2 in the moderate loadinginduced downregulation of MMP-1, modulation of MMP-1 at the transcriptional level by
CITED2 was examined by transactivation assays. CITED2 is a transcriptional regulator that
does not bind directly to DNA promoter regions, but functions by interacting with other
transcription factors or cofactors such as p300.198

For this reason, chondrocytes were co-

transfected with a 2.3 kb MMP-1 promoter-luciferase construct and either empty vector or
constructs containing CITED2, p300, or si-p300, and the promoter activity was measured using a
luciferase assay. In certain conditions, cells were subjected to moderate loading at 2.5 MPa, 1
Hz, for 1 hr. As shown in Figure 4.4, cells transfected with empty vector or si-scramble
displayed potent luciferase activity (in agreement with the MMP-1 mRNA results in Fig. 4.3),
and the activity level was further stimulated by p300 overexpression. In contrast, the MMP-1
transactivation was substantially reduced in all groups of cells overexpressing CITED2, and the
suppressive effect of CITED2 was comparable to those with either loading (2.5 MPa) or p300
knockdown (Fig. 4.4). These findings indicate that MMP-1 transcription is directly mediated by
CITED2 and p300.
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CITED2 Downregulates MMP-1 by Competing with Ets-1 for p300 Binding
We next took further steps to dissect the detailed molecular events surrounding the
CITED2 regulation of MMP-1 expression. The transcriptional co-regulator p300 is the principal
binding partner of both CITED2 and MMP-1 transactivator Ets-1.149,195,199,200 We speculated that
CITED2 may function to downregulate MMP-1 by competing with Ets-1 for p300 binding. To
test this hypothesis, we characterized the p300 complexes in cells with altered expression of
CITED2 by immunoprecipitation assays. As shown in Figure 4.5A, the formation of CITED2p300 complexes due to either loading (which upregulated CITED2) or CITED2 overexpression
was accompanied by complete displacement of Ets-1 from its p300 binding site. Conversely,
suppression of CITED2 by transfection with si-CITED2 enhanced Ets-1 binding to p300 (Fig.
4.5A). These results support our premise that the p300-CITED2 complex formed upon loading
is responsible for the effects of CITED2 on MMP-1 expression.
The direct competition between CITED2 and Ets-1 for binding to p300 was supported by
two additional observations. First, an examination of a dominant-negative (DN) p300 lacking
the CH1 domain that binds to CITED2 and Ets-1 indicated that p300 was absolutely required for
the regulation of MMP-1 by CITED2 or Ets-1. As expected, loading at 2.5 MPa reduced MMP1 and increased CITED2 expression without affecting p300, both in untransfected and vectortransfected chondrocytes. In contrast, overexpression of wild-type p300, which led to increased
complex formation between p300 and Ets-1, blocked the load-induced attenuation of MMP-1
without altering CITED2 levels (Fig. 4.5B). However, p300-DN was unable to correct the loadinduced downregulation of MMP-1. Overexpression of CITED2 under these conditions
mimicked the effects of loading (Fig. 4.5C). Second, bound GST-p300 CH1 quantified by time55

resolved fluorescence measurements of a Europium-labeled anti-GST antibody in ELISA-based
competition assays revealed a subtle difference between the half-maximal inhibitory (IC50)
concentrations for reduction of the Ets-1-p300 complex by CITED2 (0.58 nM) and of the
CITED2-p300 complex by Ets-1 (0.90 nM) (Figs. 4.5D and 4.5E). This difference suggests a
potential chondroprotective mechanism that p300, under physiological conditions, may exhibit a
slight preference for binding to its partner, CITED2, over its catabolic co-regulator Ets-1.
To identify specific regions within the binding domains of CITED2 and Ets-1 required
for MMP-1 regulation, we carried out a series of transfection experiments using deletions and
point mutations introduced into each molecule (Fig. 4.6A). In the first set of experiments, we
treated chondrocytes transfected with wild-type or mutant CITED2 with IL-1β and examined
MMP-1 mRNA and protein expression by PCR and Western blotting, respectively. We found
that the CITED2 fragment containing amino acids (aa) 224 to 256 was both necessary and
sufficient for MMP-1 downregulation, whereas a CITED2 fragment lacking this region (i.e.
fragment 1-223) did not (Fig. 4.6B). More specifically, EPEE, a mutation of the LPEL motif
found within the 224-256 amino acid region, completely abolished the downregulation of MMP1 expression, suggesting that LPEL was critical for load-induced MMP-1 regulation.
Co-transfection of chondrocytes with wild-type CITED2 and mutated forms of Ets-1
(Fig. 4.6C) showed that overexpression of CITED2 suppressed IL-1β -induced expression of
MMP-1 and that overexpression of wild-type Ets-1 partially reversed the MMP-1 suppression
caused by CITED2. However, this rescue was abolished in the transfectants overexpressing Ets1 fragments in which the transactivation domain (TAD, aa 135-243) was removed either by
truncation beyond aa 153 and 165, respectively, or through its deletion, as in the fragments ∆16656

194 and ∆178-210 (Fig. 4.6D). Most importantly, however, the fragment 153-210 fully reversed
the effects of CITED2 overexpression, suggesting that the p300-binding domain of Ets-1, which
competes with CITED2, is indeed the critical component of the TAD.
p38δ Activation Mediates the Loading-induced Transactivation of CITED2
Finally, we determined the upstream signal(s) necessary for moderate mechanical loads
to induce CITED2 expression.

Amongst several known candidates that act as potential

mechanotransducers, the MAP kinases, particularly p38, have received much attention.201,202
However, the roles played by individual p38 isoforms (p38α, p38β, p38γ, p38δ) in cartilage
mechanotransduction have not been investigated. Moderate loads of 2.5 MPa, which upregulate
CITED2 and downregulate MMP-1 (Figs. 4.7A and 4.7B), did not stimulate phosphorylation of
p38α but specifically stimulated the phosphorylation of a p38δ (Fig. 4.7C).

In contrast,

chondrocytes loaded at 10 MPa results in the phosphorylation of p38α (Fig. 4.7C), which
coincides with the upregulation of MMP-1 (Fig. 4.7B), a change that typifies a catabolic
response to non-physiological loads.

We therefore explored how p38δ regulates CITED2

expression in response to moderate loading by examining the transactivation of the 3.3 kb
CITED2 promoter.

Promoter-reporter assays using luciferase constructs transfected into

chondrocytes confirmed the stimulation of CITED2 transactivation by both loading and p38δ
overexpression, proving that p38δ is upstream of CITED2 and downstream of loading (Fig.
4.7D). Furthermore, this response was abolished by dominant-negative p38δ and si-p38δ.
Analysis of CITED2 promoter responsiveness to p38δ by means of progressive deletion
constructs showed that removal of the NF-κB-binding site did not appreciably reduce promoter
transactivation (Fig. 4.7E). Deletion of the HIF-1α response element in the (-940) CITED2
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promoter region attenuated transactivation by ~50% (Fig. 4.7E). However, while removal of one
Sp1 site in the -2300-bp CITED2 fragment produced no change in transactivation, the
subsequent deletion of three further Sp1 sites almost completely abolished promoter
responsiveness to p38δ (Fig. 4.7E). Together, this data suggests that the effect of p38δ on
CITED2 is, at least in part, mediated by HIF-1α and Sp1.
Competing with Ets-1 for p300 is a common mechanism for CITED2 regulation of MMPs 1, 2,
3, and 13
Our results suggest CITED2 may regulate MMP expression by competing with Ets-1 for
p300 binding. As MMP-2, -3, and -13 also carry Ets-1 binding sites on their promoter, we tested
that CITED2 regulates multiple MMPs through this Ets-1-p300 mechanism. Towards this end,
we constructed and transfected the CITED2 motif (LPEL) which binds to p300 and a mutant
motif unable to bind to p300 (EPEE), in chondrocytes (Fig 4.8A). Overexpression of the
mutated CITED2 motif, in contrast to the wild-type motif, was unable to downregulate MMP
expression and activity when overexpressed in C28I2 cells, suggesting that CITED2 suppression
of MMP expression is mediated through p300 binding (Fig 4.8B). To provide further evidence
and the precise regulatory mechanism that CITED2 binding to p300 prevents Ets-1 mediated
transcription of MMPs, ChIP assays were performed using an antibody against Ets-1. IL-1β,
which stimulates MMP expression in C28/I2 chondrocytes, increased binding of Ets-1 to at least
one putative Ets-1 binding site on the promoter regions of MMPs 1, 2, 3, and 13 (Fig 4.8C).
However, these protein-DNA bindings were significantly decreased when CITED2 was
overexpressed in IL-1β treated cells (Fig 4.8C). These data indicate that CITED2 downregulates
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the transactivation of MMPs 2, 3, and 13 by preventing Ets-1 from forming productive
transcriptional complexes with p300, similar to that observed with MMP-1.

Discussion
The idea that musculoskeletal tissue integrity is best maintained at moderate
(physiologic) levels of mechanical loading has long been appreciated. In muscle and bone, for
example, repair of minor tissue damage from overuse entails breakdown and removal of the
damaged tissue and replacement with newly formed matrix.203,204 On the other hand, tissue
breakdown also occurs as a result of loading insufficiency, resulting in muscle atrophy205 and
osteopenia or osteoporosis.206

While an understanding of the molecular mechanisms that

transduce mechanical stimuli into increases in bone and muscle mass is emerging, less is known
of how mechanical stimuli generated by joint movement, and the frequency and intensity of such
loads, help to maintain cartilage integrity. Accumulating clinical evidence indicates that, in
contrast to excessive or inadequate loads, continuous passive motion along with other forms of
physiological joint loading is necessary for proper joint maintenance, and joint motion can
protect cartilage from cartilage degradation 92,93,147. In this study, we show for the first time that
physiologically relevant passive loading of normal joints prevents cartilage degradation through
the upregulation of CITED2 using the p38δ pathway.
Matrix metalloproteinases (MMPs) are proteolytic enzymes responsible for the destruction
of articular cartilage. This study focused on a single MMP (MMP-1) and on its transcriptional
control by CITED2. MMP-1 was selected for this study as a prototypical catabolic enzyme
because it directly cleaves type II collagen and is highly expressed in arthritic articular
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cartilage.183,190 Moreover, since MMP-1 has only been identified recently in mice and rats,207,208
the role of MMP-1 is less understood in rodent models. Using a mutagenesis strategy of the
CITED2 p300 binding domain and ChIP assay, we further demonstrated that the CITED2 p300
binding ability is required and sufficient to suppress multiple MMPs including MMPs 1, 2, 3,
and 13 by preventing Ets-1 binding to MMP promoter sites to trigger transcription of MMPs, and
therefore repressing their expression.
Our study provides several lines of evidence that CITED2 is essential in order to mediate
the transcriptional suppression of MMP-1 by moderate hydrostatic pressure loading, and
elucidate mechanistic features of this novel pathway. 1) Analysis of CITED2 loss and gain of
function revealed that under moderate levels of intermittent hydrostatic pressure, si-CITED2
abolished the reduction in MMP-1 expression and forced overexpression of CITED2 mimicked
the effects of moderate loading by downregulating MMP-1. 2) CITED2 competed with a MMP
transactivator, Ets-1, and displaced it from the p300-Ets-1 complex to reduce MMP-1
transactivation. 3) The CITED2 nucleotide region encoding the fragment between amino acids
224 to 270 was absolutely required and sufficient to downregulate MMP-1.

4) CITED2

suppressed MMP-1 promoter activation in a process requiring p300. Taken together, these
observations strongly support our hypothesis that CITED2 mediates a chondroprotective
signaling pathway by competing with Ets-1 for p300 binding to downregulate MMP-1
expression. That our results in vivo and in vitro were in excellent agreement with respect to the
inverse relationship between expression of CITED2 and MMP-1 argue strongly that the
mechanistic relationships we established in vitro are likely to hold in vivo.
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The proposed mechanism of MMP-1 regulation by CITED2, involving competition with
Ets-1 for binding to p300, was consistent with expectations based on published binding
characteristics of CITED2 and HIF-1α for p300.195 Interestingly, however, the competition
binding studies indicated a slightly greater affinity of p300 for CITED2 than for Ets-1. To the
extent that these relationships translate to in vivo circumstances, the result suggests that this
potential regulatory switching mechanism may be slightly biased toward suppression, rather than
activation, of MMP transcription.

Such a bias might be useful to prevent overaggressive

catabolic responses to changes in the mechanical environment.
While our results demonstrated direct transcriptional regulation of MMP-1 by CITED2 in
chondrocytes, it is likely that additional regulatory mechanisms may also operate, particularly in
vivo. Virtually all cell types present in joint tissues (cartilage, bone, synovium) are
mechanoresponsive.148,209-211

Furthermore, mechanical stimulation is known to alter the

production of, as well as response to, cytokines known to regulate MMP expression, including
IL-1β and TNF-α 92,93,147.
Another novel finding of this study was that the mechanosensitive upregulation of
CITED2, which occurred in response to moderate levels of mechanical loading in vitro and in
vivo, was associated with the selective activation of a specific isoform of p38, p38δ. Members of
the p38 MAP kinase family are activated in response to mechanical stresses and a wide range of
chemical stimuli,202,212 and have been implicated in the upregulation of MMPs.213 We have
observed that high levels of loading led to neither phosphorylation of p38δ nor CITED2
upregulation. This may partially explain why CITED2 is functional only under moderate loading
with regards to the regulation of MMP expression. Conversely, excessive loading induced
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MMP-1 and phosphorylation of p38α, suggesting that the latter is likely involved in the
regulation of MMP-1. Together, these data indicate that distinct members of the p38 family can
act within the same cell population to promote and to suppress MMP-based matrix breakdown
depending on the mechanical loading environment.
In summary, we have identified a novel CITED2-mediated pathway in which CITED2,
induced by moderate loads through the activation of p38δ, suppresses MMP-1 transcription by
displacing transactivator Ets-1 from co-activator p300. The identification of this CITED2
pathway as a means to regulate MMP expression in cartilage not only provides a molecular basis
for the prevention of cartilage degradation by physiologic loads, but also offers the possibility
that this pathway could be exploited therapeutically in diseases like arthritis.
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Figures

Figure 4.1. In vivo motion knee joint motion loading device. The schematic diagram of the in
vivo device (left). Experimental setup with a rat undergoing the motion and loading protocol
(right).
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Figure 4.2.

Passive motion loading prevents cartilage degradation.

(A) Schematic

representation of the Short Protocol, where the rat hind limb is immobilized for six hours
interrupted by 1-hour of passive motion or release from immobilization under anesthesia, or the
(D) Extended Protocol, where the rat limb is immobilized for 7 days with or without a 1-hour per
day passive motion protocol. (B, E) qPCR showing fold-change in mRNA levels of MMP-1 or
(C, F) CITED2, and (G) MMP-1 (enzyme) activity after immobilization (Im), passive motion
loading (Pm), sham treatment (Sh), or no treatment (Con).

(H) Safranin O staining and

immunohistochemical localization of MMP-1, type II collagen denaturation (Col2-3/4M
antibody), and CITED2 in articular cartilage from rats undergoing the Extended Protocol.
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Statistics: One way ANOVA and Tukey’s post hoc test, *p < 0.05 versus control, n=5 rats per
group. Scale bar = 100 µm.

Figure 4.3. CITED2 is required for load-induced downregulation of MMP-1. (A, B) qPCR
showing the effect of intermittent hydrostatic pressure loads (IHP, MPa as shown, 1 Hz, 1 hour)
applied to articular cartilage explants (n=5 rats per group) or to (C, D) chondrocytes on CITED2
and MMP-1 mRNA expression and (E) CITED2 and MMP-1 protein expression detected by
Western blot.

(F, H) qPCR and (G) Western blots showing, respectively, the effect of

transfecting chondrocytes with pcDNA3.1-CITED2 or small interfering RNAs for CITED2 (siCITED2) or scrambled RNA (si-Scramble) on MMP-1 mRNA and protein expression in
response to IHP (2.5 MPa, 1Hz, 1 hour) in the absence or presence of IL-1β. *p < 0.05, versus
control, in triplicate.
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Figure 4.4. Direct effects of CITED2 and p300 on MMP-1 promoter transactivation. Effect of
co-transfecting chondrocytes with CITED2, Ets-1 or p300 in various combinations (shown)
with/without siRNA for p300 (si-p300) or IHP (2.5 MPa, 1 Hz, 1 hour) on MMP-1 promoter
activity in luciferase assays. *p < 0.05, versus vector transfected cells, in triplicate.
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Figure 4.5. CITED2 competes with Ets-1 for p300 binding. (A) Immunoprecipitation with antip300 antibody and Western blot (WB) with either anti-CITED2 or anti-Ets-1 antibodies to reveal
protein-protein interactions between Ets-1, CITED2 and p300. (B) qPCR showing the effects of
overexpressing p300 or dominant-negative p300 (p300-DN) on the relative expression of MMP1, CITED2 and p300 in response to IHP (2.5 MPa, 1Hz, 1 hour) or (C) co-transfection with wild
type CITED2 without IHP. Mean half-maximal inhibitor concentrations (IC50, nM) for (D)
CITED2 on Ets-1-p300 or (E) Ets-1 on CITED2-p300.
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Figure 4.6. CITED2 regulates MMP-1 through specific motif. (A) Effect of transfecting
chondrocytes with plasmids encoding either wild-type (WT) CITED2 or CITED2 deleted,
truncated, or point mutants on (B) MMP-1 and CITED2 mRNA (PCR) and/or protein (Western
blot) expression in the presence of IL-1β. Abbrev: CR – conserved region; ∆srj – CITED2 wildtype with deletion of 39-amino acid serine-glycine rich junction; EPEE – mutated LPEL (aa243246) motif. (C) Effect of co-transfecting wild-type Ets-1 or Ets-1 deleted or truncated mutants
with CITED2 on (D) MMP-1 and CITED2 mRNA (PCR) and/or protein (Western blot)
expression in the presence of IL-1β.
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Figure 4.7. MAP Kinase p38δ is the upstream mediator of CITED2 in response to moderate
loading. (A) qPCR showing the effect of IHP (MPa as shown, 1 Hz, 1 hour) on the expression of
CITED2 and (B) MMP-1. (C) Western blot showing p38δ and p38α activation, measured as
phosphorylation of the p38 substrate, ATF2. (D) Luciferase activity in chondrocytes transfected
with the CITED2 promoter-reporter construct after application of IHP (2.5 MPa, 1 Hz, 1 hour),
or co-transfection with wild-type or dominant negative p38δ or p38α, or (E) with sequential
deletion constructs of CITED2 co-transfected with p38δ. *p < 0.05 versus control, wild-type, or
previous deletion construct, in triplicate.
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Figure 4.8. CITED2 mimics suppression of MMPs 1, 2, 3, and 13 in chondrocytes in the
presence of IL-1β by wild-type CITED2 but not functional domain deleted CITED2.

(A)

Transfection of wild-type CITED2 but not EPEE mutant suppressed MMP gene expression and
activity in chondrocytes in the presence of IL-1β. Upper panel: Wild-type and CITED2 mutant
constructs. EPEE is a mutation of the LPEL motif found within the 224-256 amino acid region.
(B) Western blot showed overexpression of wild-type and mutant CITED2. (C) ChIP analysis
with Ets-1 binding sites on MMP promoters shows that increased Ets-1 binding after IL-1β
treatment was prevented with CITED2 overexpression. n=3/group. *=p<0.05.
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Chapter 5 – CITED2 is required for cartilage homeostasis: deletion of CITED2 in mice
leads to osteoarthritis
Abstract
Joint diseases such as osteoarthritis (OA) are a leading cause of adult disability and
characterized by progressive cartilage destruction and damage to the integrity of bone and other
joint tissues. The pathogenesis of OA is not well understood, nor is there an effective treatment
to cure or even slow its progression.

CITED2 (Cbp/p300 Interacting Transactivator with ED

rich tail 2), is a transcriptional regulator which plays critical roles in suppressing expression of
enzymes which directly cleave the cartilage extracellular matrix, such as matrix
metalloproteinases (MMPs-1, -13). In previous chapters, we demonstrated that CITED2 is a
mediator required for the loading-induced downregulation of MMPs. CITED2 downregulated
MMP expression by competing with MMP transactivator Ets-1 for binding to co-factor p300.
Reduction of CITED2 expression was associated with immobilization-caused cartilage
degradation, suggesting a critical role for CITED2 in maintaining cartilage integrity and
homeostasis. In this study, we tested whether deficiency of CITED2 is a casual factor for
cartilage degradation and arthritic diseases. We found that reductions of CITED2 expression
were associated with cartilage degradation in human and mouse OA cartilage, compared to ageand gender-matched non-OA controls. Experimental knockdown of CITED2 in adult mice, by
intra-articular gene transfer of CITED2 shRNA, or by genetic deletion in an inducible, cartilagespecific knockout mouse model, led to early OA-like cartilage pathology. Furthermore, the
knockdown of CITED2 accelerated the progression of post-traumatic OA in the destabilization
of the medial meniscus (DMM) mouse model, compared to wild-type DMM mice. We find that
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CITED2 plays its role in maintaining cartilage integrity, at least in part, by modulating
expression of MMP-13 and ADAMTS5, which are considered the predominant proteolytic
enzymes in OA pathogenesis. Restoring CITED2 expression in OA tissues may be a therapeutic
strategy for arresting or slowing OA progression.
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Introduction
Previous studies have demonstrated that CITED2 is a mechanically responsive
transcriptional regulator required to mediate cellular responses to mechanical loading that protect
against cartilage degradation.148,158 Of notice, while dynamic moderate loading induced CITED2
expression and suppressed MMPs, immobilization (reduced loading) resulted in cartilage
degradation and was associated with reduced levels of CITED2. Furthermore, knockdown of
CITED2 in vitro, abolished the loading-induced MMP downregulation, and caused an elevation
of MMP expression above its basal level. These studies allow us to ask the following questions:
Do reduced levels of CITED2 a) correlate with severity of established OA and b) increase
susceptibility of developing OA under given circumstances? What are the mechanisms through
which CITED2 mediates chondroprotection?
To address these questions, we first investigated whether there was an association
between CITED2 expression and the extent of cartilage degradation characterized by OARSI
score in human OA cartilage. We then evaluated then expression level of CITED2 during the
initiation and progression of OA in post-traumatic OA mice. We further examined whether
knockdown of CITED2 in cartilage can cause OA-like pathology. We examined the effect of
specifically deleting CITED2 in adult mice, and examined the deficiency of CITED2 involved in
OA development in post-traumatic mice using the DMM model.
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Methods
Human OA samples - Human OA specimens were collected from patients undergoing total knee
or hip replacement surgery with written consent in accordance to an IRB-approved protocol
(n=8, avg. age=70±7.3 yrs). Age- and gender-matched non-OA cartilage was obtained from
post-mortem patients without history of joint diseases. Cartilage was dissected, fixed in 10%
formalin, and embedded in paraffin for sectioning.
Induction of osteoarthritis in mice - Destabilization of the medial meniscus (DMM) in 5-6
month-old male C57BL/6 mice was carried out by transecting the medial meniscotibial ligament
(MMTL), (n=6). A 3 mm longitudinal incision over the distal patella to proximal tibial plateau.
The joint capsule immediately medial to the patellar tendon was incised with a # 15 blade and
the joint capsule opened with micro-iris scissors. Blunt dissection of the fat pad over the
intercondylar area was then performed to expose either the intercondylar region, providing
visualization of or the meniscotibial ligament of the medial meniscus. Mild hemorrhage from the
fat pad upon blunt dissection was controlled by pressure from absorption spears. The medial
meniscotibial ligament (MMTL) anchors the medial meniscus (MM) to the tibial plateau. The fat
pad over the cranial horn of the medial meniscus was dissected with Jewelers forceps. The
MMTL was identified running from the cranial horn of the medial meniscus laterally onto the
anterior tibial plateau. Sectioning of medial meniscotibial ligament was performed with a # 11
blade, gave destabilization of the medial meniscus (DMM). Control joints involved a sham
surgery in which the ligament was visualized but not transected. The joint capsule was closed
with a continuous 8-0 tapered Vicryl suture and the subcutaneous layer with 7-0 cutting Vicryl.
The skin was closed by the application of tissue adhesive.
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CITED2 suppression in vivo - Intra-articular injections of CITED2 shRNA (10 mg/10 uL PBS)
were performed followed by electroporation every 7 days in a separate set of 8- to 10-wks-old
male C57BL/6 mice. Contralateral controls received injections of PBS only followed by
electroporation (n=3).
Cited2 conditional knockout mice - Col2a1-Cre/ERT x Cited2flf mice were generated by crossing
Cited2-floxed mice with Col2a1-Cre/ERT mice
two Cited2-floxed alleles (Figure 1).

214,215

. Genotyping confirms mice with Cre and

Daily intraperitoneal injection of tamoxifen

(1mg/10g/mouse/day for 5 days) in skeletally mature, 5-6 month-old male mice resulted in
knockdown of the Cited2 gene in articular chondrocytes when assessed at 8 weeks.
Immunohistochemistry and Safranin O staining - Sections were incubated overnight at 4°C with
anti-NITEGE (cleaved aggrecan), anti-Col2 3/4M (denatured type II collagen), anti-CITED2,
anti-MMP-13 anti-ADAMTS5, or irrelevant isotype-matched antibodies as negative controls,
followed by a secondary antibody and visualization with DAB chromagen. Histological scoring
was performed by Safranin O/Fast green.

Results
Loss of CITED2 correlates with cartilage degradation in human OA and DMM mice.
In human OA cartilage samples, “healthy,” regions with strong Safranin O staining were
correlated with high levels of CITED2 expression, and low levels of aggrecan cleavage and type
II collagen denaturation. On the other hand, areas of cartilage destruction, indicated by local loss
of Safranin O staining, were correlated with low levels of CITED2 expression, and strong
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staining for cleaved aggrecan and type II collagen denaturation (Fig 5.2A). Similarly, CITED2
was detected in healthy mouse cartilage, but was expressed at low levels in degenerated cartilage
4 weeks after OA induction by DMM (Fig 5.2B).
CITED2 suppression produces OA-like changes in normal mouse cartilage.
We next determined the direct effect of CITED2 suppression on cartilage homeostasis
after intra-articular injection of CITED2 shRNA in normal mouse knees followed by
electroporation. Two weeks following CITED2 knockdown, a loss of Safranin O staining was
detected in the articular cartilage along with a loss of CITED2 expression, an increase in the
amounts of cleaved aggrecan and denatured type II collagen, compared to the PBS-injected
contralateral controls (Fig 5.3A).
Deletion of CITED2 in adult mice results in early OA
Deletion of Cited2 in the mouse articular cartilage of Cited2 conditional KO (cKO) mice
was validated at the DNA, mRNA and protein levels 8 weeks after tamoxifen administration
(data not shown). Cited2 cKO mice developed early OA as evidenced by histologic analysis
(OARSI score 1 in cKO vs 0 in wild-type) and Safranin O staining (Fig 5.3B) while the cartilage
in wild-type controls were healthy. Cited2 cKO exhibited higher levels of denatured type II
collagen, aggrecan cleavage as revealed by Col2 ¾M and NITEGE, respectively (Fig 5.3B).
CITED2 deletion accelerates post-traumatic OA disease progression
As reduced levels of CITED2 may be associated with the pathogenesis of OA, we
compared OA disease progression in wild-type and Cited2 KO mice subject to DMM. Cited2
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cKO exhibited more severe cartilage degradation and further elevated levels of type II collagen
denaturation (Col2 3/4M) and aggrecan cleavage (NITEGE) (Fig 5.3C).
CITED2 suppression upregulates MMP-13 and ADAMTS-5 expression.
Since CITED2 suppression led to increased damage to both type II collagen and aggrecan
in the cartilage extracellular matrix, we examined the role of CITED2 in regulating the
expression of both MMP-13 and ADAMTS-5, which respectively are the most efficient
proteolytic enzymes which cleave the above mentioned matrix components. In human and
mouse OA, reduced levels of CITED2 were associated with increased levels of both MMP-13
and ADAMTS-5 (Fig 5.4A).

Knockdown of CITED2, by intra-articular gene transfer of

CITED2 shRNA (Fig 5.4B) or conditional deletion of CITED2 (Fig 5.4C), led to an increase in
the number of chondrocytes expressing MMP-13 and ADAMTS-5.
CITED2 represses ADAMTS-5 expression by negatively regulating syndecan-4.
As CITED2 deletion significantly elevated ADAMTS-5 expression, we explored the
potential mechanism that CITED2 represses ADAMTS-5 expression, focusing on syndecan-4,
which is critical for the regulation of ADAMTS-5.187 Immunohistochemical analysis showed
syndecan-4 is elevated in the cartilage of Cited2 cKO mice and was associated with the increase
of ADAMTS-5 (Fig 5.5A). Importantly, gene transfer of Cited2 reduced both syndecan-4 and
ADAMTS-5 in the articular cartilage, suggesting Cited2 represses ADAMTS-5 by, at least in
part, negatively regulating syndecan-4 (Fig 5.5B).
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Discussion
In this chapter, we showed that levels of CITED2 expression is lower in the cartilage of
OA patients compared to age- and gender-matched controls. We provide the first evidence that
reduced CITED2 is associated with cartilage degradation in human OA. By examining the level
of CITED2 expression in post-traumatic OA, we found that reduction of CITED2 expression is
associated with the progression of cartilage degradation. The consistent results of reduced
CITED2 expression associated with cartilage degradation in both human and mouse OA suggests
deficiency of CITED2 may be an important common factor in OA initiation and disease
progression. The loss-of-function studies by knocking down CITED2 by intra-articular gene
transfer in mice provide preliminary, experimental, and direct evidence that deficiency of
CITED2 is a casual factor of OA. Furthermore, using genetic deletion of CITED2 in tamoxifen
inducible, cartilage-specific CITED2 adult knockout mice, we found that deletion of CITED2
resulted in early OA development after 8 weeks. Of notice, deletion of a gene specifically from
the adult cartilage alone seldom generates phenotypic changes.216 This study provides clear and
strong evidence which indicates that CITED2 is required for cartilage integrity maintenance.
Cartilage degradation such as in OA is a complex pathologic process. The initiation and
progression of which can be, and usually results from more than “one hit” from disease risk
factors such as aging, overuse, genetics and joint injuries. Studies have shown that reduced
CITED2 expression is a function of aging in tendon stem cells, and preliminary studies also
indicate that levels of CITED2 expression decline with aging in chondrocytes, both in human
and in mice, suggesting that CITED2 may be an underlying mechanism of aging as a risk factor
for cartilage degradation in OA.
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Post-traumatic injuries are a critical risk factor for OA. Studies show that up to 50% of
individuals develop OA 10-12 years after injuries to the meniscus or ACL. In a well established
post-traumatic OA model based on a meniscus injury, we found that disease progression is
associated with reduced levels of CITED2 expression, suggesting that deficiency of CITED2
plays a role in post-traumatic injury-induced OA. Our data show that deletion of CITED2 in
adult cartilage combined with a meniscus injury accelerates OA initiation and progression and
results in a more severe cartilage degradation and OA pathology than CITED2 deletion or DMM
injury alone. Taken together, these data suggest that deficiency of CITED2, which may be a
factor underlying aging and injuries for its role as a cartilage degradation susceptibility factor, or
may be also a genetic factor which accelerates cartilage degradation when combined with other
environmental, intrinsic, or extrinsic factors.
Cartilage degradation in joint diseases such as OA is characterized by an imbalance
between the anabolic and catabolic activities of chondrocytes, yet the set of regulatory
mechanisms governing that balance remain incompletely understood.

The finding that

deficiency of CITED2 is associated with or casually related to upregulation of MMPs, such as
MMP-13 and ADAMTS such as ADAMTS5 in human and mouse OA suggest CITED2 plays an
anti-catabolic role via, at least in part, downregulation of these proteolytic enzymes.
In previous studies, we have identified CITED2 as a transcriptional repressor of MMPs.
The finding that the upregulation of ADAMTS5 in the CITED2 knockout mice suggest
aggrecanases such as ADAMTS5 may be another target of CITED2 in its chondroprotective
pathway. To this end, our preliminary data indicate CITED2 may downregulate ADAMTS5 in
chondrocytes by repressing ADAMTS5 activation via syndecan-4. In addition to its role in
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suppressing expression of MMPs/ADAMTS reported in this study, CITED2 plays a critical role
in cell fate determination. As age is a major risk factor for developing OA, and chondrocyte
senescence has been suggested to lead to cartilage degradation, further elucidating the role of
CITED2 in this chondroprotective pathway may not only provide a new avenue for the insight of
cartilage degradation in arthritic disease, but potential targets for disease prevention and
treatment.
Figures

Figure 5.1. Conditional knockout of Cited2 gene in the cartilage of adult mice.
Intraperitoneal injections of Tamoxifen (1mg/10g/mouse/day for 5 days) into 6-months-old
male and female inducible Cited2 conditional KO mice (Col2a1CreERTxCited2fl/fl)64,65
completely and specifically knocked out the Cited2 gene in mouse articular cartilage. A.
Mouse crossbreeding strategy. B. Validation of exclusive Cited2 knockout at the DNA,
mRNA and protein levels 12 weeks after Tamoxifen administration. WT: age and gender
matched wild type control mice. KO: Col2a1CreERTxCited2fl/fl mice receiving Tamoxifen
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dissolved in corn oil; Sham: Col2a1CreERTxCited2fl/fl

that received corn oil without

Tamoxifen. NC: negative control without sample.

Figure 5.2. Reduced levels of CITED2, detected by immunohistochemistry and real-time qPCR
are associated with increased OA severity, and increased degradation of cartilage matrix
components aggrecan (NITEGE) and type II collagen (Col2 3/4M) in human OA (A) and mouse
OA (destabilization of the medial meniscus, DMM) cartilage (B), compared to age and gendermatched non-OA controls.
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Figure 5.3. CITED2 knockdown by intra-articular gene transfer of CITED2 shRNA for 2 weeks
in wild-type mice (male, C57Bl/6, 10-12 weeks) (A) or conditional knockout of Cited2 (Cited2
cKO) in the articular cartilage for 8 weeks (male, Cited2flf x Col2al-CreERT, 10-12 weeks) (B)
led to early OA, and increased the amount of cleaved aggreacan and denatured type II collagen
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in the articular cartilage compared to sham (A) or wild-type littermates (B). DMM in Cited2
cKO mice increased severity of OA and increased cleaved aggrecan and denatured type II
collagen compared to wild-type littermates (C).

Figure 5.4.

(A) Reductions in CITED2 expression were associated with decreases in

chondrocytes expressing MMP-13 and ADAMTS5 in human and mouse OA cartilage, compared
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to non-OA controls. (B) Experimental knockdown of Cited2 in mouse articular cartilage by
intra-articular gene transfer of CITED2 shRNA or (C) conditional knockout led to increases in
MMP-13 and ADAMTS5 compared to non-knockdown controls.

Figure 5.5. CITED2 represses ADAMTS-5 expression by negatively regulating syndecan-4.
(A) Level of syndecan-4 was elevated in CITED2 conditional knockout mice (cKO) which was
associated with elevated levels of ADAMTS5. (B) CITED2 gene transfer reduced the levels of
both syndecan-4 and ADAMTS-5 in DMM cartilage. Cell counts of syndecan-4, ADAMTS-5,
and CITED2 in conditional knockout mice vs wild-type, and in DMM+vehicle vs.
DMM+CITED2. *=p<0.05.
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Chapter 6 – The Use of CITED2 for Chondroprotection
Abstract
There is currently no cure for degenerative joint diseases which feature the progressive
degradation of articular cartilage. So far, most pharmacologic treatments mainly concentrate on
secondary effects of such diseases, such as relieving pain and improving joint function, but fail
to address the underlying disease progress. CITED2, induced by moderate mechanical loading,
is a transcriptional regulator which suppresses the expression of multiple MMPs and ADAMTS,
enzymes which directly cleave the cartilage extracellular matrix. Cartilage degradation, as seen
in OA, is associated with elevated levels of MMPs and ADAMTS, and reductions in CITED2
expression. Experimental knockdown of CITED2 by intra-articular gene transfer of CITED2
shRNA or genetic deletion of CITED2 in the articular cartilage, led to early cartilage degradation
and damage to the cartilage extracellular matrix components aggrecan and type II collagen. In
this study we tested the hypothesis that restoration of CITED2 would slow progression of
cartilage degradation.

Gene transfer of CITED2 in two models of cartilage degradation,

collagen-induced arthritis, and destabilization of the medial meniscus, slowed progression of
cartilage breakdown. Immunohistochemistry revealed CITED2 gene transfer also prevented
degradation to the type II collagen and aggrecan components of the cartilage matrix.
Furthermore, EGCG, a green tea extract, was a small molecule inducer of CITED2, and daily
administration of EGCG slowed progression of post-traumatic OA. Taken together, our studies
suggest CITED2-based therapies have the potential to arrest or slow cartilage degradation in
diseases such as osteoarthritis and rheumatoid arthritis.
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Introduction
There is currently no cure for degenerative joint diseases which feature the progressive
degradation of articular cartilage.77 So far, most pharmacologic treatments mainly concentrate
on secondary effects of such diseases, such as relieving pain and improving joint function, but
fail to address the underlying disease progress.217
Based on the studies in the previous chapters, we have established that: 1) with a unique
mechanical loading response characteristic and via a newly identified pathway, CITED2 plays a
novel role in mediating loading-induced MMP downregulation (Chapters 3&4), 2) CITED2 is
required for cartilage integrity maintenance and CITED2 deficiency was associated with
cartilage degradation in human OA and post-traumatic OA in mice, knockdown of CITED2
through intra-articular gene transfer of shCITED2 RNA caused OA like pathologic changes, and
most importantly, deletion of CITED2 specifically from adult mouse cartilage resulted in not
only in OA-like phenotypic changes, but also accelerated the progression of post-traumatic OA
(Chapter 5). 3) Furthermore, over-expression of CITED2 represses MMP expression in cultured
chondrocytes in vitro, suggesting CITED2 is a transcriptional repressor of MMP expression and
its anti-catabolic action can be triggered by not only mechanical loading, but also by other
physical or chemical means to protect cartilage. Together, this suggests that CITED2-based
therapies may have efficacy in preventing and/or treating cartilage degradation in arthritic
diseases.
In this study, we tested the hypothesis that restoration of CITED2 would slow progression of
cartilage degradation. To test this, we used intra-articular CITED2 gene transfer in two cartilage
degradation models: destabilization of the medial meniscus (DMM), a model of post-traumatic
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OA, and collagen-induced arthritis (CIA), a model of rheumatoid arthritis. Furthermore, we
examined the efficacy of CITED2 in chondroprotection, by administrating epigallocatechin 3gallate (EGCG),,218 a hypothesized small molecule activator of CITED2, to mice in the posttraumatic OA model. EGCG increases phosphorylation of p38δ,219 a transactivator of CITED2.
EGCG has also been reported to reduce levels of pro-inflammatory cytokines,220 inhibit
production of inflammatory mediators,221,222 and suppress expression of several MMPs223 and
ADAMTS. 224 However, whether EGCG has the capacity to alter OA progression is unknown.

Methods and Materials
CITED2 gene transfer in mice - CITED2 gene transfer was carried out by weekly intra-articular
injections of a plasmid encoding CITED2 cDNA (25µg) followed by electroporation (200V, 0.10
ms pulse length, 4 pulses each polarity) into the DMM knee while the vehicle controls received
injections of an empty vector followed by electroporation.
Destabilization of the medial meniscus - One day after the first gene transfer, surgical induction
of OA (destabilization of the medial meniscus) was performed in the right hind limbs of wildtype mice (male, 20-24 weeks) as described in Chapter 5. Immediately after surgery, mice were
allowed normal cage activity.
Collagen-induced arthritis (CIA) - Bovine type II collagen solution (Chondrex) was emulsified
in Freud’s complete adjuvant at 4°C. Under an IACUC-approved protocol, male SpragueDawley rats (6-8 wk) were immunized by two intradermal injections of 100µl emulsion (1µg
collagen/µl) at the base of the tail given one week apart.
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In vivo gene transfer efficiency - In order to determine transfection effiency of in vivo gene
transfer, 25µg of pcDNA3.1-GFP was injected into the intra-articular cavity of the right knees of
rats (n=2), followed by electroporation (250V, 0.10 ms pulse length, 4 pulses each polarity).
Contralateral limbs were injected with an empty vector followed by electroporation. Forty-eight
hours after transfection, rats were sacrificed and their hind limbs were fixed in 10% formalin,
decalcified, and embedded in paraffin. Sections were cut (5-7μM), mounted on glass slides,
coverslipped, and visualized under a microscope with a GFP filter.
CITED2 gene transfer in CIA rats - After the collagen booster injection, and at weekly intervals
thereafter, rats received 25µg of pcDNA3.1 encoding human wild-type CITED2 cDNA by intraarticular injection followed by electroporation. Intra-articular injections of an empty vector were
administered to the contralateral limbs followed by electroporation. Animals were sacrificed 0,
8, 11, 14, 17, 21, and 28 days after the first injection (n=2/timepoint). Articular cartilage from
distal femur and tibial plateau were harvested, flash frozen, and lysed for Western blots. At Day
28, parallel articular cartilage samples were fixed in formalin, decalcified and processed for
histology (n=3/group).
Induction of osteoarthritis in mice and EGCG treatment - Immediately after the DMM surgery in
male, 5-6 months mice, 100 μl of EGCG (25mg/kg, Sigma, dissolved in PBS) or vehicle was
administered via intraperitoneal injection 5 days/week for 4 weeks.

At the end of the

experiment, hind limbs were fixed in formalin, decalcified and embedded in paraffin
(n=6/group).
Immunohistochemistry, Safranin O staining, and OARSI score evaluation - Paraffin sections (57μM) were incubated overnight at 4°C with antibodies against cleaved aggrecan (NITEGE,
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Ibex), denatured type II collagen (Col2-3/4M, Ibex), MMP-13 (Abcam), and ADAMTS-5
(Abcam) followed by incubation with anti-mouse or anti-rabbit secondary antibody and
visualization with DAB chromagen (Vector Laboraties). Negative controls were stained with
irrelevant isotype-matched antibodies. Safranin O-fast green staining was used to visualize
proteoglycans in the articular cartilage. OA was severity evaluated by OARSI scoring system225.

Results
CITED2 gene transfer prevents cartilage degradation in CIA model
To determine whether electroporation of CITED2 would prevent cartilage degradation,
we first established the effectiveness of gene transfer into rat articular cartilage. Forty-eight
hours after intra-articular gene transfer of a GFP plasmid, we found GFP-producing
chondrocytes in all three zones of the articular cartilage (Fig 6.1). Following electroporation,
CITED2 levels assessed by Western blot increased until Day 14, then remained high throughout
the experimental period (Fig 6.1). Collagen-induced arthritis rats treated with CITED2 gene
transfer, compared to vehicle control, exhibited increased expression of CITED2 in articular
chondrocytes (81±6% vs. 22±3%, p<0.05), diminished loss of Safranin O staining (OARSI score
0.18±0.20 vs. 1.12±0.33, p<0.05), lower levels of denatured type II collagen and a reduced
number of chondrocytes positive for MMP-13 (79±5% vs 40±3%) and ADAMTS5 (89±6% vs.
51±4%, p<0.05) (Fig 6.1).
CITED2 gene transfer slows cartilage degradation in DMM model

89

Four weeks after DMM, the articular cartilage in the DMM limb in the vehicle-treated mice
exhibited Safranin O loss, cartilage fibrillation, and an average OARSI score of 2.5±0.5 (Fig
6.2). In contrast, the cartilage in the DMM limb in the CITED2 gene transfer mice exhibited less
Safranin O loss and cartilage fibrillation, and a lower OARSI score (1.1±0.4, p<0.05) compared
to vehicle-treated controls (Fig 6.2).
Immunohistochemical staining showed that CITED2 gene transfer strongly reduced levels of
cleaved aggrecan (NITEGE) and fragmented/denatured type II collagen (Col2 3/4M), in
comparison to vehicle-treated controls (Fig 6.2). These data further confirms that CITED2 gene
transfer improves the integrity of the articular cartilage by preserving both collagen and aggrecan
components in post-traumatic OA mice.
In vivo administration of EGCG slows progression in DMM OA mice
To confirm EGCG induces expression of CITED2, we treated human C28/I2 chondrocytes
with 100µM EGCG. Three hours after treatment, we found expression of CITED2 at the mRNA
and protein levels was increased (Fig 6.3).
Four weeks after DMM, the articular cartilage in the DMM limb in the vehicle-treated mice
exhibited a mild-OA pathological change characterized by Safranin O loss, cartilage fibrillation,
and an average OARSI score of 2.0±0.5 (Fig 6.4A, B). In contrast, the cartilage in the DMM
limb of EGCG-treated mice exhibited less Safranin O loss and cartilage fibrillation, and the
mean OARSI score (1.2±0.4) was significantly lower compared to vehicle-treated controls
(p<0.05, Fig 6.4A, B). Sham-operated mice receiving either vehicle or EGCG treatment did not
exhibit pathologic changes in the articular cartilage and had OARSI scores of 0.15±0.25 and
0.12±0.31, respectively (Fig 6.4A, B).
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Immunohistochemical staining showed that EGCG treatment strongly reduced the levels of
the type II collagen cleavage epitope (Col2 3/4M) in DMM mice compared to vehicle-treated
DMM mice (Fig 6.5). Based on the immunostaining intensities of 6 randomly selected areas of
the articular cartilage at 4 weeks following DMM, type II collagen cleavage in vehicle-treated
controls increased to 1.18-fold above sham-treated vehicle mice, and was reduced to 0.97-fold in
EGCG-treated animals (p<0.05, Fig 6.5A, B). Sham animals treated with vehicle or EGCG had
no significant immunostaining for type II collagen degradation at 4 or 8 weeks (Fig 6.5A,B).
Immunohistochemical staining similarly showed that EGCG treatment reduced the levels of
cleaved aggrecan (NITEGE) in DMM mice compared to vehicle-treated DMM mice (Fig. 6.6).
At 4 weeks after DMM, the intensity of aggrecan cleavage was reduced to 1.07-fold in the
EGCG-treated compared to 1.29-fold in the vehicle control (p=0.08, Fig 6.6A, B). Sham animals
treated with vehicle or EGCG did not exhibit significant immunostaining for cleaved aggrecan at
4 weeks (Fig 6.6A,B).
Cartilage matrix degradation is mainly mediated by two major families of proteolytic
enzymes, namely MMPs and ADAMTS 21. In particular, MMP-13 is the most potent enzyme in
cleaving type II collagen, the major form in articular cartilage, while ADAMTS-5 is the
primarily proteolytic enzyme that cleaves aggrecan, the major proteoglycan in cartilage
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. We

therefore examined whether reduction of MMP-13 and ADAMTS5 could underlie the
chondroprotective effect of EGCG using immunohistochemistry.
At 4 weeks following DMM, the percentage of MMP-13 positive cells was reduced from
60% in vehicle-treated mice to 22% in EGCG-treated mice (p<0.05).

MMP-13 positive

chondrocytes in the vehicle-treated DMM mice were distributed in all three zones of the articular
cartilage of the femoral and tibial condyles. In contrast, the MMP-13 positive chondrocytes in
91

EGCG-treated mice were localized mainly in the middle and deep zones (Fig 6.7A, B). Levels
of MMP-13 positive cells in the articular cartilage of EGCG-treated sham mice were at a level
(4%) similar to those in sham vehicle mice (5%) (Fig 6.7A, B).
Similarly, at 4 weeks following DMM surgery, EGCG reduced the percentage of
ADAMTS5 positive cells from 61% in vehicle-treated mice to 22% in the articular cartilage
(p<0.05, Fig 6.8A, B). EGCG treatment appeared to exert no measurable effect on the levels of
ADAMTS5 in chondrocytes in the articular cartilage in the sham animals treated either with
vehicle (5%) or EGCG (4%) (Fig 6.9A, B). EGCG did not significantly alter the percentage of
ADAMTS5 positive cells in sham-operated mice (Fig. 6.8A,B).
These data further suggest that EGCG treatment improves the integrity of the articular
cartilage by preserving both collagen and aggrecan components in post-traumatic OA mice, and
that EGCG exerts chondroprotection, at least in part, by suppressing MMP-13 and ADAMTS5
expression.

Discussion
Cartilage degradation is mediated directly by enzymes which cleave the cartilage
extracellular matrix, such as matrix metalloproteinases (MMPs) and a disintegrin and
metalloproteinase with thrombospondin motifs (ADAMTS). Inhibitors for these proteolytic
enzymes have been explored as therapeutic strategies to treat OA. However, clinical trials with
MMP inhibitors so far have been met with limited success and resulted in side effects including
musculoskeletal pain and inflammation.104-106 These adverse effects have been mainly attributed
to the lack of selectivity of these inhibitors, and over suppression of their targets. Matrix
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metalloproteinases share structural similarities and are susceptible to regulation by broadspectrum inhibitors.87 Poor selectivity is problematic because in addition to matrix remodeling,
MMPs/ADAMTS play important roles in wound healing, angiogenesis, development,
morphogenesis, and bone remodeling.88,89 Clearly, pharmacologic solutions for treating OA
need to define the correct molecular targets and ensure proper modulation of these targets.
The first aims of the studies in this chapter were to test the concept that gain-of-function of
CITED2 is able to prevent or slow the progression of RA and OA. It has been established that
the etiology of OA and RA are different.21 Cartilage degradation in RA is due to high levels of
inflammatory cytokines. Different from RA, cartilage degradation in OA can be caused by
complex risk factors, including genetic, aging, and overuse/trauma.77

While the initiating

mechanisms for cartilage degradation differ in RA and OA, cartilage destruction is the hallmark
of both diseases. In both, activation of MMPs and ADAMTS, the predominant enzyme families
in directly cleaving the cartilage extracellular matrix, is shared in the molecular pathology.2 Our
previous studies established a CITED2-mediated pathway in downregulating MMP expression.
In this study, overexpression of CITED2 not only significantly reduced expression of MMP-13,
but also ADAMTS-5, a proteolytic enzyme that degrades aggrecans. Together, the findings in
this study indicate restoring or elevating CITED2 in inflammatory arthritic joints or in posttraumatic OA joints can significantly slow cartilage degradation in early phases of the disease,
but the efficacy of CITED2 in treating cartilage degradation after disease onset remains to be
tested.
Our findings suggest that CITED2 exerts great potential for chondroprotection in both RA
and OA cases; 2) CITED2 plays its role, at least by targeting two major proteolytic enzymes
MMP-13 and ADAMTS-5, and thus preserves cartilage matrix components type II collagen and
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aggrecans. The action of targeting multiple catabolic enzymes may be an underlying mechanism
for CITED2 as an effective treatment in chondroprotection. Furthermore, CITED2 selectively
repressed, but did not completely suppress expression of MMP-13 and ADAMTS-5. Therefore,
CITED2-based therapeutic strategies may be a promising treatment that can avoid the adverse
effects of MMP inhibitors while exerting efficacy in preventing or slowing cartilage degradation.
Overexpression of CITED2 in articular cartilage proved the concept that CITED2 can be
used as a molecular target to turn on anti-catabolic action by suppressing not only MMPs but
also ADAMTS. However, gene transfer-based therapies are neither patient friendly, or risk-free.
Furthermore, as inhibiting cartilage degradation in OA and RA may require decades-long
treatment, long-term use, safety, and convenience are critical criteria for any treatment strategy.
Based on the multiple-stimuli responsive nature of CITED2, we thought to develop a
nutraceutical treatment based on the activation of CITED2 and examined efficacy of
nutraceutical activation in a post-traumatic model of OA.

Through a targeted screening

approach, we found EGCG, a green tea extract, is an activator of CITED2, and slowed
progression of post-traumatic OA. It is unclear whether chondrocytes may be densensitized to
daily stimulation of EGCG, but this possibility can be tested by monitoring CITED2 levels with
treatment time.
EGCG has been used as a general nutritional supplement for anti-cancer, and anti-aging, and
the dosage of EGCG for such purposes has been proven to be safe and non-toxic.218 In human
subjects, daily doses of 800mg EGCG for 4 weeks have been reported to be safe and well
tolerated.226 EGCG is mostly absorbed by the small intestine, and may undergo gastrointestinal
inactivation.226

Therefore, oral administration of EGCG may reduce its bioavailability.

Accordingly, in our study, we chose to administer EGCG via intraperitoneal injection, which has
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been shown to lead to a higher bioavailability compared to oral consumption.226 Future trials
should consider optimizing EGCG bioavailability if given orally. Taking together, this study
provides direct evidence that CITED2 activation reached by nutraceutical compounds may be a
valid approach for the prevention and treatment of cartilage degradation.

95

Figures

Figure 6.1. Increased expression of CITED2 by gene transfer exerts chondroprotection in CIA
rats. Top: Experimental protocol, transfection efficiency of CITED2 gene transfer, and
expression of CITED2 in CIA rats throughout the experiment. Bottom: CITED2 gene transfer
prevented degradative changes within the articular cartilage in the CIA model. Gene transfer
prevented loss of Safranin O staining, and decreased expression of MMP-13 and ADAMTS-5.
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Figure 6.2.

Intra-articular CITED2 gene transfer reduced OA severity, increased CITED2

expression, and prevented damage to aggrecan and type II collagen in the cartilage of DMM
mice after 4 weeks, compared to vehicle-treated controls.
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Figure 6.3. Green tea extract, epigallocatechin-3-gallate (EGCG, 100 µM), upregulates
expression of CITED2 in C28/I2 human chondrocytes. *p < 0.05 versus control, n=3.

Figure 6.4. EGCG administration slows progression in early and mid-stage OA in DMM mice.
Safranin O staining and OARSI score of sham- or DMM-operated mice treated with vehicle or
EGCG at 4 (A, B) weeks following surgery (*p<0.05, ANOVA, n=6/group). Arrows heads
indicate the areas of cartilage fibrillation or erosion, and arrows indicate loss of Safranin O
staining.
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Figure 6.5. EGCG administration reduced the degradation of type II collagen in the articular
cartilage matrix. Immunohistochemical staining of type II collagen cleavage epitope (Col2
3/4M) and relative staining intensity of the articular cartilage matrix of sham- or DMM-operated
mice treated with vehicle or EGCG at 4 (A, B) weeks following surgery (*p<0.05, ANOVA,
n=6/group, Scale bar=100µM).

Figure 6.6. EGCG administration reduced the degradation of aggrecan in the articular cartilage
matrix. Immunohistochemical staining of cleaved aggrecan (NITEGE) and relative staining
intensity in the articular cartilage matrix of sham- or DMM-operated mice treated with vehicle or
EGCG at 4 (A, B) weeks following surgery (*p<0.05, ANOVA, n=6/group, Scale bar=100µM).
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Figure 6.7. EGCG administration reduced MMP-13 levels in the articular cartilage.
Immunohistochemical staining of MMP-13 and percentage of MMP-13 positive cells in the
articular cartilage of sham- or DMM-operated mice treated with vehicle or EGCG at 4 (A, B)
weeks following surgery (*p<0.05, ANOVA, n=6/group, Scale bar=100µM).

Figure 6.8. EGCG administration reduced ADAMTS5 levels in the articular cartilage.
Immunohistochemical staining of ADAMTS5 and percentage of ADAMTS5 positive cells in the
articular cartilage of sham- or DMM-operated mice treated with vehicle or EGCG at 4 (A, B)
weeks following surgery (*p<0.05, ANOVA, n=6/group, Scale bar=100µM).
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Chapter 7 – Global Discussion
Mechanical loading is the most important factor for cartilage homeostasis while
overloading and underloading are considered to be non-physiologic and lead to cartilage
degradation.

Moderate loading is required for the maintenance of cartilage integrity, but

mechanisms mediating these effects are largely unknown. Based on the literature review and our
previous studies, we hypothesized that CITED2 mediates a mechanical pathway in
chondroprotection; appropriate levels of CITED2 are critical for cartilage integrity; and
restoration, or increasing levels of CITED2 exerts efficacy in prevention and treatment for
cartilage degradation in arthritis. Accordingly, the gene expression response of CITED2 to
mechanical loading, the CITED2-mediated mechanically sensitive anti-catabolic pathway, and
the potential use of CITED2 for chondroprotection were investigated at the molecular, cellular,
and tissue level in vitro and in vivo in this dissertation.
To understand the role of CITED2 in mediating loading-induced MMP downregulation,
we analyzed CITED2 and MMP expression in immobilized joints with daily, 1hr, remobilization.
The results that CITED2 downregulation in immobilized limbs was associated with MMP-1
upregulation and cartilage degradation, and the upregulation of CITED2 associated with the
downregulation of MMP-1 and chondroprotection was the first hint that CITED2 may play a
critical role in maintaining cartilage integrity. We further determined the machinery of this
mechanical regulation and found that CITED2 regulates MMP expression by competing with
MMP transactivator Ets-1 for binding to limited amounts of co-activator p300.

The

mechanotransduction pathway involved the phosphorylation of p38δ, which transactivated
CITED2 through the HIF-1 and Sp1 binding sites on its promoter region.
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Upon the establishment and characterization of the biomechanical response of CITED2
and its critical role in mediating loading-induced downregulation of CITED2 in chondrocytes
both in vitro and in vivo, we thought that CITED2 deficiency may be a casual factor for cartilage
degradation, especially considering the case that immobilization caused cartilage degradation
and was associated with reduced CITED2 expression levels. This notion was further supported
by the association of reduced levels of CITED2 and increased levels of MMP-13 and ADAMTS5 in human and mouse OA and knockdown of CITED2 via intra-articular injection of CITED2
shRNA caused OA-like changes in mice (Chapter 5). We therefore established an inducible and
cartilage-specific CITED2 knockout mouse model and examined the cartilage to investigate this
possibility. The finding that deletion of CITED2 in adult mice results in early OA and further,
that CITED2 deletion accelerates post-traumatic OA disease progression, provides direct
evidence that CITED2 is essential for cartilage integrity maintenance and deficiency of CITED2
is a casual factor of cartilage degradation. The results also suggest that deficiency of CITED2
leads to cartilage degradation in OA, at least in part, by reducing the chondrocyte stress-response
capacity.
Based on our findings, CITED2 is required for cartilage integrity maintenance, and
several gain-of-function studies such as overexpressing CITED2 can mimic the effects of
moderate loading by downregulating expression of MMPs. We therefore hypothesized that
CITED2 is a molecular switch / target and activation of CITED2 may prove to be a novel
strategy for chondroprotection which can be used for preventing and therapeutic treatment of
cartilage degradation in arthritic disease.

To this end, in Chapter 6, we first conducted

experiments to prove the concept in inflammatory arthritis by using the collagen-induced arthritis
model, and we found that weekly intra-articular gene transfer of CITED2 significantly reduced
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cartilage degradation.

Next, we examined the CITED2 chondroprotection effect in post-

traumatic OA and found a similar efficacy. Interestingly, gene transfer of CITED2 reduced
expression of MMP-13 and ADAMTS-5 levels and immunohistochemistry showed such
treatment reduced aggrecan and type II collagen degradation. Further, we examined the efficacy
of a CITED2 activator, EGCG, an extract derived from green tea in OA prevention. We found
EGCG treatment slowed progression of OA, and prevented degradation to the cartilage matrix
components aggrecan and type II collagen, at least in part, by suppressing expression of MMP13 and ADAMTS. This suggests CITED2 can be used as a molecular target via mechanical or
other means of activation for chondroprotection.
The unique biomechanical response of CITED2 and the novel pathway that CITED2
mediates provides novel insight in understanding the underlying mechanisms of cartilage
homeostasis maintenance, pathogenesis of cartilage degradation, and may be more importantly, a
potential strategy and molecular target for prevention and treatment of cartilage degradation in
OA, RA, and other arthritic diseases.
Based on the studies in this thesis, four major conclusions can be drawn.
1. CITED2 was induced in an intensity-dependent manner in response to hydrostatic pressure
loading, and was required to mediate the loading-induced down-regulation of MMP-1, -2, -3, and
13.

The overexpression of CITED2 mimicked these anti-catabolic actions of moderate

mechanical loading.
2. Physiological joint loading prevented disuse-caused cartilage degradation associated with
induced expression of CITED2. CITED2 exerted its chondroprotective actions by competing
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with MMP transactivator Ets-1 for binding to limited amounts of co-activator p300, and is
transactivated by p38δ, through HIF-1α and Sp1 binding sites on its promoter region.
3. Deficiency of CITED2 is associated with loss of cartilage integrity in human and mouse OA,
and experimental knockout of CITED2 led to up-regulation of not only MMP-13 and but
ADAMTS-5 and resulted in cartilage degradation and OA.
4. Restoration of CITED2 slowed progression of cartilage breakdown in post-traumatic OA
model in mice, and collagen-induced arthritis model in rats, two models of cartilage degradation.
Activating

CITED2,

with

small

molecule

EGCG,

exerted

significant

efficacy

in

chondroprotection in also showed slow down the disase progression in post-traumatic OA mice
model.
This thesis study focused on the anti-catabolic role of CITED2. Of notice, as a co-factor,
CITED2 may also play a role in cartilage homeostasis by regulating chondrocyte fate such as
chondrocyte hypertrophy senescence, and apoptosis. Future studies will focus on elucidating
these cell fate-related mechanisms and determining their role in chondroprotection, which may
reveal novel insight for understanding the regulatory mechanisms of cartilage homeostasis and
strategies / targets for the prevention and treatment of cartilage degradation.
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